

Author Index to Volumes 18, 19, and 20

Aarnaes, S.L., 19:221
 Ahluwalia, G.S., 18:161
 Alami, S.Y., 20:151
 Albert, M.J., 18:145, 19:47, 20:209
 Alden, B., 20:13
 Aldridge, K.E., 18:191, 18:235, 19:227, 20:
 135
 Alfa, M.J., 18:121
 Alós, J.-I., 19:69
 Altaie, S.S., 18:141, 18:175
 Alvarez, M., 18:95
 Ampel, N.M., 18:83
 Anand, C.M., 18:229
 Anderson, J.D., 18:79
 Anderson, M.R., 19:235
 Anderson, S.C., 19:203
 Ansaruzzaman, M., 19:47
 Appelbaum, P.C., 18:25
 Araj, G.F., 20:151
 Arnold, R.R., 20:69
 Axelrod, P., 18:251
 Ayers, L.W., 18:235
 Azim, T., 18:145, 19:47

Bacon III, A.E., 18:205
 Baddour, L.M., 19:245
 Baker, C.N., 19:167
 Bale, M.J., 18:151, 19:9, 19:65, 19:75, 19:175
 Balows, A., 19:135, 19:249, 20:119
 Barrett, M.S., 19:93, 19:183
 Bartlett, M.S., 18:197
 Bes, M., 19:25
 Biedenbach, D.J., 19:93
 Biehle, J.R., 19:101
 Bingen, E., 18:263
 Bland, S., 19:25
 Blanding, J., 19:221
 Bloom, J.W., 18:83
 Bolmström, A., 19:187
 Bonfiglio, G., 19:163
 Borges, C.E., 19:121
 Brackman, M.A., 18:117
 Brady, S.L., 18:197
 Brighty, K.E., 19:235
 Brookings, E., 18:181
 Budd, N., 18:111
 Bumgardner, R.V., 18:1
 Buschelman, B., 19:9, 19:75

Cantrell, H.F., 19:111, 20:143
 Carroll, K., 20:163
 Castaldi, M.J., 19:235
 Cavalieri, S.J., 19:101
 Chang, S.-C., 19:143
 Chapin-Robertson, K., 18:259
 Chee, S.L., 19:89
 Cherubin, C.E., 20:21
 Chow, A.W., 19:39
 Chowdhury, A., 18:145
 Chua, R., 20:195
 Clarke, A.M., 20:27
 Cogollos, R., 19:69
 Cohen, M., 18:25

Cohen, M.A., 18:31, 18:41
 Cook, R.A., 18:89
 Cooksey, R.C., 18:215
 Cooper, G., 20:1
 Courtney, R.R., 19:61
 Crane, L.R., 18:89
 Crawford, J.T., 18:215
 Croco, J.L., 20:213
 Cutie, E., 18:95

da Glória Siqueira Carvalho, M., 20:61
 Dalton, M.T., 20:1
 DeAngelis, P.L., 20:77
 de Araujo Vieiralves, L.F., 19:121
 de la Maza, L.M., 19:221
 Della Latta, P., 18:13
 Dessens, M., 19:151
 Dill, S.R., 18:259
 Di Nuzzo, A.R., 20:113
 Dionisio, D., 18:7
 DiTomasso, J.P., 18:83
 Doern, G.V., 18:243, 20:109
 Donabedian, H., 18:111
 Dryja, D., 18:141, 18:175
 Dulworth, J.K., 18:117
 Durkin, M.M., 18:197

Edinger, R., 19:61
 Eng, R.H.K., 18:105
 Ephgrave, K.S., 19:197
 Ephraim, D.A., 18:137
 Erwin, M.E., 18:125, 18:243, 19:65, 19:183,
 19:203, 20:49, 20:93, 20:213
 Espinel-Ingroff, A., 19:9, 19:217, 20:81, 20:
 87

Fan-Havard, P., 18:105
 Fang, K.-M., 18:69
 Faruque, A.S.G., 20:209
 Fasola, E.L., 19:57
 Fekete, T., 18:251
 Fekety, R., 18:205
 Felmlee, T.A., 18:219
 Finegold, S.M., 19:129
 Finlay, J.E., 20:171
 Fleurette, J., 19:25
 Fluoroquinolone Resistance Surveillance
 Group, 19:203
 Fonseca, K., 18:229
 Forthal, D., 19:221
 Forward, K.R., 20:1
 Fraser, S., 20:195
 Frei, R., 18:167
 Freney, J., 19:25
 Friedland, L.R., 20:187
 Fuchs, P.C., 18:151
 Fung-Tomc, J.C., 18:129
 Furness, K., 18:175

Gadea, I., 19:171
 Gage, J.W., 18:41
 Galgiani, J.N., 18:89, 20:81
 Gallimore, B., 19:39
 Gallis, H.A., 18:89

Gaskins, D., 18:181
 Gayowski, T., 19:1
 Gegúndez, M.I., 19:171
 Gelfand, M., 18:235
 Gerlach, E.H., 18:243
 Getsinger, L.J., 19:101
 Goldman, M., 20:175
 Gómez-Garcés, J.L., 19:69
 Gootz, T.D., 19:235
 Grant, C.E., 18:1
 Greenaway, C., 18:121
 Grigoriew, G.A., 19:89

Haase, D., 20:181
 Halkias, K., 18:181
 Hammond, G.W., 18:161
 Harrell, L.J., 20:121
 Harrison, L.H., 18:211
 Haskell, S.L., 19:235
 Hassett, D.J., 20:187
 Haugen, T.H., 20:13
 Hegewald, S., 20:163
 Heifetz, C.L., 18:31, 18:41
 Heinzer, I., 20:117
 Henderberg, A., 18:235
 Himmelright, I.M., 19:245
 Hindler, J., 18:243
 Hoban, D.J., 18:49, 18:167
 Hoban, S., 18:121
 Hohl, P., 19:121
 Hollick, G.E., 19:61
 Hollis, R.J., 19:197, 20:127
 Hoque, S.S., 20:209
 Hossain, A., 18:145, 19:47
 Houston, A.K., 18:57
 Hsieh, W.-C., 19:143
 Huang, M.B., 19:167
 Huband, M.D., 18:31
 Huber, M.B., 20:113
 Hubinette, M.M., 20:27
 Hunt, J.M., 18:219

Ieven, M., 18:157
 In Vitro Susceptibility Surveillance Group,
 19:111

Jacobs, M.R., 18:25
 Janney, A., 18:235
 Jenkins, S., 18:181
 Jennings, J.M., 20:213
 Jensen, C., 19:137
 Jesudason, M.V., 18:75
 Joannides, E.T., 18:31
 John, T.J., 18:75, 18:211
 Johnson, D.M., 18:125
 Johnson, F.B., 19:137
 Johnson, H.W., 18:79
 Johnson, M., 18:235
 Johnson, W.M., 20:181
 Jones, R.N., 18:49, 18:57, 18:61, 18:125, 18:
 133, 18:151, 18:167, 18:243, 19:33, 19:65,
 19:93, 19:149, 19:175, 19:183, 19:203, 20:

49, 20:93, 20:143, 20:159, 20:167, 20:203, 20:213
 Jorgensen, J.H., 20:41

Kabir, I., 19:47
 Kaka, S., 20:105
 Kanga, J.-M., 19:121
 Kehrberg, E.N., 19:203
 Kenny, M.T., 18:117
 Kerr, E., 20:1
 Kessler, R.E., 18:129
 Keystone, J., 19:89
 Khosid, H.E., 20:195
 Kissling, M., 19:121
 Kitching, D.A., 20:195
 Kleiman-Wexler, R.L., 19:197
 Klisko, B., 18:161
 Kluchka, C., 18:229
 Klugman, K.P., 20:105
 Kobayashi, J., 18:19
 Koontz, F.P., 18:151, 19:183
 Korten, V., 20:45
 Kraatz, J., 20:175
 Krajden, M., 19:89
 Kreter, B., 18:251

Lalitha, M.K., 18:211
 Lancaster, M., 19:9
 Lankford, R.B., 19:111, 20:143
 Laverdière, M., 19:39
 Law, L., 19:89
 Lee, C.-H., 18:197
 Lee, N., 18:69
 Lee, T.-T., 18:69
 Legere, E.A., 20:195
 Lewis, J., 18:181
 Livermore, D.M., 19:163
 Lomefloxacin Study Group, 20:93
 Low, D.E., 19:5, 20:195
 Lucena, R., 19:121
 Luh, K.-T., 19:143
 Lungu, O., 18:13
 Lunz, R., 20:105
 Lyons, E., 20:195

MacArthur, R.D., 18:111
 Macdonald, N.E., 20:181
 MacLaren, D.M., 19:151
 Mailoux, G.B., 18:41
 Marco, F., 18:167
 Mariscal, D., 19:15
 Marrama, L., 20:109
 Marrero, M., 18:95
 Marshall, S.A., 19:33
 Martín, R., 19:15
 Martino, R.L., 18:259
 Martín-Rabadán, P., 20:33
 Martins Teixeira, L., 20:61
 Mathew, T., 18:121
 Matthey, S., 20:13
 Mayer, J., 20:163
 McDonald, C.L., 18:259
 McEvoy, P.L., 18:201
 McGuirk, P.R., 19:235
 Meli, M., 18:7
 Menon, A.G., 20:187
 Meservey, M.A., 18:31, 18:41

Messer, S.A., 20:127
 Mieles, L., 19:1
 Mills, K., 19:179
 Mirrett, S., 20:121
 Molitoris, E., 19:129
 Moody, J.A., 19:57
 Morales, E., 18:95
 Moreno, F., 20:41
 Morice, N., 19:227
 Morthland, V.H., 19:197
 Muder, R.R., 20:99
 Mukundan, S., 18:75
 Murmans, M., 19:151
 Murphy, S.P., 20:49
 Murray, B.E., 20:45
 Murray, P.R., 19:111

Naidu, A.S., 20:69
 Nguyen, M.H., 20:99
 Nicholson, D., 20:13
 Nieto, E., 19:171
 Niubò, J., 19:15
 Noble, R.C., 19:51
 North American Ofloxacin Study Group, 18:49

O'Donnell, E., 18:111
 O'Donovan, C.A., 18:105
 Ólafsson, J.H., 18:101
 Olsen, M.A., 19:19
 Olszewski, C., 18:111
 Ongsansoy, E., 18:121
 O'Quinn, K.J., 19:5
 Otero, A., 18:95
 Overman, S.B., 19:51

Paisley, N., 20:1
 Pálsdóttir, R., 18:101
 Pappas, P.G., 18:89
 Patel, M.P., 19:5
 Pattyn, S., 18:157
 Peñate, G., 18:95
 Pérez, J.L., 19:15
 Pérez-Cecilia, E., 20:33
 Perl, T.M., 18:151
 Persing, D.H., 18:219
 Peterson, E.M., 19:221
 Peterson, L.R., 19:57
 Pfaller, M.A., 18:1, 18:151, 19:9, 19:75, 19:197, 20:127, 20:203
 Phillips, A.M., 19:5
 Pierson, C.L., 18:235
 Pignatari, A.C., 18:167
 Poonia, K., 19:39
 Pottage, J.C., Jr., 18:89
 Poupart, J.A., 20:171
 Prasad, E.S., 20:57
 Privitera, G., 19:157
 Provinciael, D., 18:157
 Putnam, L.R., 20:213

Qadri, F., 18:145
 Quality Control Study Group, 19:65

Ramadan, M.A., 20:7
 Rand, K., 18:181
 Rangaraj, M., 18:263

Raszka, W.V., Jr., 18:201
 Reising, S.F., 20:187
 Reller, L.B., 18:235, 20:121
 Rennie, K.A., 20:57
 Restieri, C., 19:39
 Reverdy, M.E., 19:25
 Rex, J.H., 19:9
 Rhomberg, P.R., 18:151, 19:75, 19:175, 20:159
 Rihs, J.D., 19:1
 Rinaldi, M.G., 19:9
 Rittenhouse, S.F., 20:171
 Robbie, L., 20:109
 Roberts, G.D., 18:219
 Rogés, G., 18:95
 Roland, G.E., 18:31, 18:41
 Root, P.P., 19:19
 Rozee, K.R., 20:181
 Ruddy, R.M., 20:187

Sabria-Leal, M., 19:197
 Sader, H.S., 20:93, 20:203
 Safran, C., 18:263
 Salam, M.A., 20:209
 Saldaña, C.J., 20:33
 Salfinger, M., 19:81
 Sanchez, M.L., 18:61
 Sánchez-Portocarrero, J., 20:33
 Sanders, C.V., 18:235
 Saramago Stern, C., 20:61
 Sartor, V.E., 20:163
 Satishchandran, V., 18:251
 Sato, Y., 18:19
 Saubolle, M.A., 19:101
 Schiro, D.D., 18:191, 18:235, 19:227, 20:135
 Schlievert, P.M., 19:245
 Schmieder, B.J., 19:235
 Schmitz, P.I.M., 19:151
 Schoenknecht, F., 18:235
 Scott-Taylor, T.H., 18:161
 Segreti, J., 20:175
 Sesnie, J.C., 18:31
 Sewell, D.L., 18:1
 Shanholtzer, C.J., 19:57
 Shapiro, M.A., 18:31
 Shibli, A.M., 20:7
 Shiroma, Y., 18:19
 Sigvaldadóttir, E., 18:101
 Silverstein, S., 18:13
 Simonetti, M.T., 18:7
 Simor, A.E., 19:5, 20:195
 Simpson, H.E., 19:5
 Singh, N., 19:1
 Skillman, L.P., 18:201
 Skulnick, M., 19:5, 20:195
 Small, G.W., 19:5
 Smeets T., 19:151
 Smid, I., 19:81
 Smith, J.W., 18:197
 Smith, R.J., 19:245
 Smith, S.M., 18:105
 Sobonya, R.E., 18:83
 Soriano, F., 19:171
 Souza, I.E., 20:13
 Spangler, S.K., 18:25
 Speier, S., 19:221
 Spitzer, E.D., 18:137
 Sridharan, G., 18:75, 18:211

Steele-Moore, L., 18:175, 20:81, 20:87
Steingrímsson, Ó., 18:101
Steinhoff, M.C., 18:211
Stobberingh, E.E., 19:151
Stockman, L., 18:219
Stratton, C.W., 20:21
Sutcliffe, J.A., 19:235
Sutton, L.D., 20:143

Takara, M., 18:19
Tawfik, A.-K.F., 20:7
Tecson-Tumang, F.T., 18:105
Tenover, F.C., 19:167
Tilton, R.C., 18:235
Toma, H., 18:19
Tomayko, J.F., 20:45
Tortoli, E., 18:7
Trenholme, G.M., 20:175
Trombley, C.L., 18:79
Truant, A., 18:251
Tubau, F., 19:15
Tumah, H., 18:251

Unicomb, L., 19:47
Utrup, L.J., 20:171
Uwaydah, M.M., 20:151


Vael, K., 18:157
Väldest, O., 18:95
Van Klinger, B., 19:151
Van Overmeire, B., 18:157
Van Reempts, P., 18:157
Villareal, K.M., 18:89

Waites, K., 18:181
Walmsley, S., 19:89
Wang, J., 18:197
Wanger, A., 19:179
Wehrli, M., 20:117
Weigel, P.H., 20:77
Weiner, M.H., 20:41
Weitzman, I., 18:13
Wenman, W.M., 20:57
Wenzel, R.P., 18:89

Werkmeister, L., 19:197
Wexler, H.M., 19:129
Wilkins, J., 18:235
Williams, J.A., 18:1
Wold, S.A., 18:41
Woods, G.L., 20:113
Woodwell, J., 18:251

Yamane, N., 18:167
Yang, J., 19:89
Yangco, B., 18:181
Yoder, S.L., 18:41
Young, S.A., 19:197
Yu, V.L., 19:1

Zabransky, R.J., 20:113
Zambardi, G., 19:25
Zapardiel, J., 19:171
Zappelini, M., 19:121
Zbinden, R., 20:117
Zemcov, S.J.V., 20:27



Subject Index to Volumes 18, 19, and 20

Abbott IMx microparticle enzyme immunoassay, for *Toxoplasma*-specific IgG, 19:19-24

Abdomen
Candida spp. in, 20:33-40
Mobiluncus mulieris in, 20:163-165
Streptococcus anginosus in, 19:70-73

Accuprobe tests
 for mycobacteria, 18:137-139
 for *Staphylococcus aureus*, 19:5-8

Acinetobacter calcoaceticus
 amoxicillin-clavulanate against, 18:185
 cefaclor against, 18:185
 cefepime against, 18:170
 cefixime against, 18:185
 ceftazidime against, 18:170
 cefuroxime against, 18:185
 ciprofloxacin against, 18:185
 FK-037 against, 18:170
 fleroxacin against, 18:185
 lomefloxacin against, 18:185
 ofloxacin against, 18:185
 trimethoprim-sulfamethoxazole against, 18:185

Acinetobacter spp.
 amikacin against, 19:151-156
 cefepime against, 18:170, 19:33-38
 cefotaxime against, 18:61-68
 ceftazidime against, 18:170, 19:151-156
 ciprofloxacin against, 18:50-56, 18:61-68, 19:151-156
 DU-6859a against, 18:125
 FK-037 against, 18:170, 20:27-32
 fluoroquinolones against, 18:181
 gentamicin against, 19:151-156
 imipenem against, 19:151-156
 in Lebanese antimicrobial susceptibility study, 20:151-158
 ofloxacin against, 18:50-56
 Pasco Gram-negative nonfermenter system for, 19:61-63
 piperacillin against, 19:151-156
 piperacillin-tazobactam against, 19:151-156
 Ro 23-9424 against, 18:61-68
 Ro 25-0534 against, 18:61-68
 ticarcillin-clavulanic acid against, 19:151-156

Acquired immunodeficiency syndrome (AIDS)
Mycobacterium genavense in, 18:7-12
 sporotrichosis in, 18:111-115

Acridine orange, for detecting false-positive BACTEC blood culture bottles, 20:121-125

Acridinium-ester-labeled DNA probes, for mycobacteria, 18:137-139

Actinobacillus ureae
 ceftriaxone against, 20:105-107
 penicillin against, 20:105-107

Adenoviruses
 in enteric clinical specimens, 18:161-166
 pseudoepidemic of, in neonatal intensive care unit, 18:157-159

transport media for viability maintenance of, 19:137-142

Aeromonas hydrophila
 cefepime against, 18:170
 ceftazidime against, 18:170
 FK-037 against, 18:170

Aeromonas spp., FK-307 against, 20:27-32

Agar dilution methods
 in anaerobe susceptibility testing, 18:25-30
 in bacterial vaginosis and peritonitis, 20:213-220
 for *Bacteroides fragilis*, 20:135-142
 for *Corynebacterium* spp., 19:171-173
 for enterococci, 20:113-116
 Etest validated against, 19:151-156
 inoculum effects on, 19:163-166
 for *Legionella* spp., 19:175-178
 for *Neisseria gonorrhoeae*, 18:175
 for *Mycobacterium avium-intracellulare*, 19:179-181
 for *Mycobacterium tuberculosis*, 19:179-181
 for *Pseudomonas aeruginosa*, 19:39-46

Agar screen plate method, for methicillin-resistant *Staphylococcus aureus*, 18:121-124

AIDS. See Acquired immunodeficiency syndrome

AM3. See Antibiotic Medium 3

Amikacin
 against *Acinetobacter* spp., 19:151-156
 against *Citrobacter freundii*, 19:151-156
 against *Enterobacter cloacae*, 19:151-156
 against *Enterococcus faecalis*, 19:151-156
 against *Escherichia coli*, 19:151-156
 against Gram-negative bacilli, 20:175-179
 against *Klebsiella* spp., 19:151-156
 against *Mycobacterium chelonei*, 19:183-186
 against *Mycobacterium fortuitum*, 19:183-186
 against *Mycobacterium genavense*, 18:10
 against *Nocardia* spp., 19:101-110
 against *Proteus* spp., 19:151-156
 against *Pseudomonas aeruginosa*, 19:151-156
 against *Serratia marcescens*, 19:151-156
 against staphylococci, 20:175-179
 against *Staphylococcus aureus*, 19:151-156, 20:175-179
 against *Streptococcus pneumoniae*, 20:175-179

Aminoglycosides
 against enterococci, 20:61-67
 against *Enterococcus faecium*, 20:41-43
 false resistance to, 18:133-135
 against *Pseudomonas stutzeri*, 19:51-56
 in US national surveillance study, 19:204-215

Aminoglycoside-ceftriaxone, against *Pseudomonas aeruginosa*, 19:39-46

Amoxicillin-clavulanic acid
 against *Escherichia coli*, 18:263-265
 against Gram-negative bacilli, 18:181-189
 against *Nocardia* spp., 19:101-110

Amoxicillin-probenecid, against *Neisseria gonorrhoeae*, 19:121-127

Amphotericin, against *Sporothrix schenckii*, 18:111-115

Amphotericin B
 against *Candida lusitaniae*, 20:127-133
 against *Candida* spp., 18:89-94, 19:75-80, 20:33-40
 against *Torulopsis glabrata*, 19:75-80
 against yeasts, 19:9-13

Ampicillin
 against *Corynebacterium* spp., 19:171-173
 against *Enterobacteriaceae*, 20:143-149
 against enterococci, 19:57-60, 20:61-67
 against *Enterococcus faecium*, 18:105-109, 20:41-43
 against *Enterococcus* spp., 20:143-149
 against Gram-negative anaerobic rods, 18:25-30
 against *Haemophilus influenzae*, 18:41-47, 20:143-149
 lactoferrin interaction with *Salmonella* spp. and, 20:69-75
 against *Listeria monocytogenes*, 20:21-25
 against *Moraxella catarrhalis*, 20:143-149
 against *Neisseria gonorrhoeae*, 19:121-127
 against *Pseudomonas aeruginosa*, 20:143-149
 against *Staphylococcus aureus*, 18:41-47

Ampicillin-sulbactam
 against *Bacteroides capillosus*, 19:227-234
 against *Bacteroides fragilis*, 18:235-241, 19:227-234, 20:213-220
 against *Clostridium* spp., 19:227-234, 20:213-220
 against *Enterobacteriaceae*, 20:143-149
 against *Enterococcus* spp., 20:143-149
 against *Eubacterium* spp., 19:227-234
 against *Fusobacterium* spp., 19:227-234, 20:213-220
 against Gram-negative bacilli, 19:111-120
 against Gram-positive cocci, 19:111-120
 against *Haemophilus influenzae*, 20:143-149
 against *Lactobacillus* spp., 20:213-220
 against *Mobiluncus* spp., 20:213-220
 against *Moraxella catarrhalis*, 20:143-149
 against *Peptostreptococcus* spp., 19:227-234, 20:213-220
 against *Porphyromonas* spp., 19:227-234
 against *Prevotella bivia/disiens*, 20:213-220
 against *Prevotella* spp., 19:227-234
 against *Pseudomonas aeruginosa*, 20:143-149
 against *Veillonella parvula*, 19:227-234

Amplicor test, for *Chlamydia trachomatis*, 20:195-201

Antibiotic Medium 3 (AM3), *Candida* spp. in, 18:89-94

Antibodies
 to *Chlamydia pneumoniae*, 18:229-233
 to *Clostridium difficile*, 18:205-209
 to cytomegalovirus, 20:109-112
 to *Strongyloides stercoralis*, 18:19-23
 to varicella-zoster virus, 20:117

API 20GP system, for staphylococci, 18:151-155

API Staph-Trac system, for staphylococci, 18:151-155

Artifactual chemoluminescence, in Accuprobe tests, 18:137-139

Ascitic fluid, in spontaneous bacterial peritonitis, 19:1-4

Aspergillus peritonitis, in continuous ambulatory peritoneal dialysis, 20:99-103

Azithromycin, against *Haemophilus influenzae*, 18:243-249

Aztreonam
 against *Enterobacter* spp., 18:251-258
 against Gram-negative bacilli, 19:111-120
 against Gram-positive cocci, 19:111-120
 against *Klebsiella* spp., 18:251-258
 against *Pseudomonas aeruginosa*, 18:251-258

Bacillus spp.
 cefepime against, 18:167-173
 ceftazidime against, 18:167-173
 FK-037 against, 18:167-173

Bacitracin, against *Enterococcus faecium*, 18:105-109

BACTEC 12B media, for mycobacteria, 18:137-139

BACTEC 13A blood cultures, for mycobacteria, 18:137-139

BACTEC nonradiometric culture system, for spontaneous bacterial peritonitis, 19:1-4

BACTEC NR 6A and 7A blood culture bottles, Gram stain/acridine orange-negative, 20:121-125

BACTEC radiometric system
 for *Mycobacterium avium-intracellulare*, 19:179-181
 for *Mycobacterium genavense*, 18:7-12
 for *Mycobacterium tuberculosis*, 19:179-181

Bacteremia
Enterococcus faecium in, 20:41-43
Oerskovia xanthineolytica in, 18:259-261

Bacteroides capillosus
 amoxicillin-clavulanate against, 19:227-234
 ampicillin-sulbactam against, 19:227-234
 ceftriaxone against, 19:227-234
 ceftriaxone-tazobactam against, 19:227-234
 metronidazole against, 19:227-234
 piperacillin-tazobactam against, 19:227-234
 tazobactam against, 19:227-234
 ticarcillin-clavulanate against, 19:227-234

Bacteroides fragilis group
 amoxicillin-clavulanate against, 18:25-30, 18:235-241, 19:227-234
 ampicillin against, 18:25-30
 ampicillin-sulbactam against, 18:235-241, 19:227-234
 cefmetazole against, 18:235-241
 cefoperazone against, 18:235-241
 cefoperazone-sulbactam against, 18:235-241
 cefotaxime against, 18:61-68, 18:235-241, 20:135-142, 20:213-220
 cefotetan against, 18:235-241
 cefoxitin against, 18:25-30, 18:235-241, 20:135-142
 ceftizoxime against, 18:235-241, 20:135-142
 ceftriaxone against, 18:235-241, 19:227-234, 20:135-142
 ceftriaxone-tazobactam against, 19:227-234
 chloramphenicol against, 18:25-30
 ciprofloxacin against, 18:61-68, 19:129-133, 19:235-243
 clindamycin against, 18:25-30, 19:129-133, 20:213-220
 CP-99,219 against, 19:235-243
 fleroxacin against, 19:129-133
 grepafloxacin against, 19:129-133
 imipenem against, 18:235-241, 19:129-133, 20:213-220
 metronidazole against, 19:129-133, 19:227-234, 20:135-142
 piperacillin against, 18:25-30, 20:135-142
 piperacillin-tazobactam against, 18:25-30, 18:235-241, 19:227-234
 Ro 23-9424 against, 18:61-68
 Ro 25-0534 against, 18:61-68
 sparfloxacin against, 19:235-243
 tazobactam against, 19:227-234
 ticarcillin against, 18:25-30
 ticarcillin-clavulanate against, 18:25-30, 19:227-234

Bacteroides spp.
 amoxicillin-clavulanate against, 18:25-30

ampicillin against, 18:25-30
 cefoxitin against, 18:25-30
 chloramphenicol against, 18:25-30
 clindamycin against, 18:25-30
 piperacillin against, 18:25-30
 piperacillin-tazobactam against, 18:25-30
 ticarcillin against, 18:25-30
 ticarcillin-clavulanate against, 18:25-30

Bartels Prima enzyme immunoassay, for *Toxoplasma*-specific IgG, 19:19-24

Bartels Prima System Toxin enzyme immunoassay, for *Clostridium difficile*, 20:1-5

Bartel's viral transport medium, virus survival in, 19:137-142

Bauer-Kirby disk diffusion
 for *Enterobacter* spp., 18:251-258
 for *Klebsiella* spp., 18:251-258
 for *Pseudomonas aeruginosa*, 18:251-258

Becton Dickinson radiometric system, in isolation of *Mycobacterium genavense*, 18:7-12

β-Lactamases
 extended spectrum, 20:203-208
 in US national surveillance study, 19:204-215

β-Lactams
 against *Enterococcus faecalis*, 18:31-39
 against *Escherichia coli*, 18:31-39
 against Gram-negative bacilli, 19:111-120
 against Gram-positive cocci, 19:111-120
 against *Haemophilus influenzae*, 18:31-39
 against *Klebsiella oxytoca*, 18:31-39
 against *Klebsiella pneumoniae*, 18:31-39
 against *Legionella pneumophila*, 18:31-39
 against *Moraxella catarrhalis*, 18:31-39
 against *Neisseria gonorrhoeae*, 18:31-39
 against *Proteus mirabilis*, 18:31-39
 against *Staphylococcus aureus*, 18:31-39
 against *Staphylococcus epidermidis*, 18:31-39
 against *Staphylococcus saprophyticus*, 18:31-39
 against *Streptococcus group A*, 18:31-39
 against *Streptococcus group B*, 18:31-39
 against *Streptococcus milleri* group, 19:70-73
 against *Streptococcus pneumoniae*, 18:31-39

Biapenem
 against *Enterococcus faecalis*, 19:65-68
 against *Pseudomonas aeruginosa*, 19:65-68
 against *Staphylococcus aureus*, 19:65-68

Bioassay quantitation, of ramoplanin, 18:117-119

BioMerieux Vitek enzyme-linked fluorescent assay, for *Toxoplasma*-specific IgG, 19:19-24

Blocking assay, for chlamydial antigen, 18:101-104

Blood cultures
 cytomegalovirus in, 19:15-18
 enterococci in, 20:61-67
Enterococcus faecalis in, 19:197-202
Pseudomonas stutzeri in, 19:51-56
Salmonella typhi in, 18:75-78
 staphylococci in, 18:1-5, 18:151-155
Staphylococcus aureus in, 19:5-8

Streptococcus pneumoniae in, 19:157–161, 20:187–193

Brain vessels, *Sporothrix schenckii* in, 18:111–115

Bronchoalveolar lavage smears, *Pneumocystis carinii* in, 18:197–199

Bronchoscopic diagnosis, of *Coccidioides immitis*, 18:83–87

Broth microdilution method
for *Bacteroides fragilis*, 18:235–241, 20:135–142
CP-99219 in, 20:167–170
inoculum density and, 18:191–195
for staphylococci, 19:167–170

Buffered charcoal–yeast extract
for *Legionella pneumophila*, 20:159–162
for *Legionella* spp., 19:175–178

Buffered yeast extract agar, for *Legionella* spp., 19:175–178

Buffy-coat specimens, cytomegalovirus in, 20:13–19

Buoyant density centrifugation, of hyaluronic acid capsules on group A streptococci, 20:77–80

Bush group I β -lactamase-producing strains, cefepime against, 19:33–38

Bush group II enzymes, cefquinome and, 20:49–55

Cambridge Bioscience immunoassays, of adenoviruses, 18:161–166

Campylobacter spp., DU-6859a against, 20:45–47

Candida albicans
amphotericin B against, 19:10
fluconazole against, 19:10, 19:218–219
5-fluorocytosine against, 19:10, 19:218–219

Candida krusei
amphotericin B against, 19:10
fluconazole against, 19:10, 19:218–219
5-fluorocytosine against, 19:10, 19:218–219

Candida lusitaniae
amphotericin B against, 20:127–133
fluconazole against, 19:219, 20:127–133
5-fluorocytosine against, 19:219, 20:127–133
itraconazole against, 20:127–133

Candida parapsilosis
amphotericin B against, 19:10
fluconazole against, 19:10, 19:218–219
5-fluorocytosine against, 19:10, 19:218–219

Candida spp.
amphotericin B against, 18:89–94, 19:75–80, 20:33–40
cifofungin against, 18:89–94
D0870 against, 19:75–80
fluconazole against, 19:75–80, 20:81–91
5-fluorocytosine against, 18:89–94, 19:75–80
itraconazole against, 19:75–80
in shunt infection, 20:33–40

Candida tropicalis
amphotericin B against, 19:10
fluconazole against, 19:10, 19:218–219

5-fluorocytosine against, 19:10, 19:218–219

CAT. See Ceftamet pivoxil

Catheters
Aspergillus in, 20:99–103
Candida spp. in, 20:40
Oerskovia xanthineolytica in, 18:259–261

Cefaclor
against *Citrobacter diversus*, 18:130
against *Citrobacter freundii*, 18:130
against *Corynebacterium* spp., 18:130
against *Enterobacter* spp., 18:129
against *Enterococcus faecalis*, 18:34, 18:130
against *Escherichia coli*, 18:35, 18:130
against Gram-negative bacilli, 18:129, 18:181–189
against *Haemophilus influenzae*, 18:34, 18:41–47, 18:129–132
against *Haemophilus parainfluenzae*, 18:130
against *Klebsiella oxytoca*, 18:35, 18:130
against *Klebsiella pneumoniae*, 18:35, 18:130
against *Legionella pneumophila*, 18:34
against *Moraxella catarrhalis*, 18:34–35, 18:129–132
against *Morganella morganii*, 18:35
against *Neisseria gonorrhoeae*, 18:35
against *Proteus mirabilis*, 18:35, 18:130
against *Serratia marcescens*, 18:130
against *Staphylococcus aureus*, 18:33, 18:41–47, 18:130
against *Staphylococcus epidermidis*, 18:33, 18:130
against *Staphylococcus haemolyticus*, 18:130
against *Staphylococcus hominis*, 18:130
against *Staphylococcus saprophyticus*, 18:33–34, 18:130
against *Streptococcus agalactiae*, 18:34
against *Streptococcus immitis*, 18:130
against *Streptococcus pneumoniae*, 18:130
against *Streptococcus pyogenes*, 18:34
against *Streptococcus sanguis*, 18:130
against *Streptococcus* spp., 18:130

Cefalexin, lactoferrin interaction with *Salmonella* spp. and, 20:69–75

Cefazolin, in US national surveillance study, 19:203–215

Cefdinir (FK482)
against *Enterococcus faecalis*, 18:31–39
against *Escherichia coli*, 18:31–39
against *Haemophilus influenzae*, 18:31–39, 18:41–47
against *Klebsiella oxytoca*, 18:31–39
against *Klebsiella pneumoniae*, 18:31–39
against *Legionella pneumophila*, 18:31–39
against *Moraxella catarrhalis*, 18:31–39
against *Neisseria gonorrhoeae*, 18:31–39
against *Proteus mirabilis*, 18:31–39
against *Staphylococcus aureus*, 18:31–47
against *Staphylococcus epidermidis*, 18:31–39
against *Staphylococcus saprophyticus*, 18:31–39
against *Streptococcus* group A, 18:31–39
against *Streptococcus* group B, 18:31–39
against *Streptococcus pneumoniae*, 18:31–39

Cefepime
against *Acinetobacter calcoaceticus*, 18:170
against *Acinetobacter* spp., 18:170
against *Aeromonas hydrophila*, 18:170
against *Bacillus* spp., 18:167–173
against ceftazidime-resistant isolates, 19:33–38
against *Citrobacter diversus*, 18:168
against *Citrobacter freundii*, 18:168, 20:49–55
against *Corynebacterium jeikeium*, 20:49–55
against *Enterobacter aerogenes*, 18:168
against *Enterobacter cloacae*, 18:168, 20:49–55
against *Enterobacteriaceae*, 18:167–173
against *Enterobacter sakazakii*, 18:168
against *Enterobacter* spp., 18:167–173
against enterococci, 18:167–173, 20:49–55
against *Enterococcus avium*, 18:171
against *Enterococcus faecalis*, 18:171
against *Enterococcus faecium*, 18:171
against *Enterococcus* spp., 18:171
against *Escherichia coli*, 18:168
against *Flavobacterium* spp., 18:170
against *Flavobacterium* spp., 18:167–173
against Gram-negative bacilli, 18:167–173
against Gram-positive cocci, 18:167–173
against *Haemophilus influenzae*, 20:49–55
against *Klebsiella oxytoca*, 18:168
against *Klebsiella pneumoniae*, 18:168
against *Moraxella catarrhalis*, 20:49–55
against *Morganella morganii*, 18:168
against *Neisseria gonorrhoeae*, 20:49–55
against *Proteus mirabilis*, 18:168
against *Providencia rettgeri*, 18:168
against *Providencia* spp., 18:167–173
against *Providencia stuartii*, 20:49–55
against *Pseudomonas aeruginosa*, 18:167–173, 20:49–55
against *Pseudomonas* spp., 18:167–173
against *Salmonella* spp., 18:168
against *Serratia liquefaciens*, 18:167–173
against *Serratia marcescens*, 18:169
against *Serratia* spp., 18:169
against staphylococci, 18:171
against *Staphylococcus aureus*, 18:167–173, 18:205, 20:49–55
against *Staphylococcus epidermidis*, 18:171
against *Staphylococcus haemolyticus*, 18:171
against *Staphylococcus hominis*, 18:171
against *Staphylococcus saprophyticus*, 18:171
against streptococci, 18:167–173
against *Streptococcus* spp., 20:49–55
against *Xanthomonas maltophilia*, 18:167–173

Cefixime
against *Enterococcus faecalis*, 18:34
against *Escherichia coli*, 18:35
against Gram-negative bacilli, 18:181–189
against *Haemophilus influenzae*, 18:34
against *Klebsiella oxytoca*, 18:35
against *Klebsiella pneumoniae*, 18:35
against *Legionella pneumophila*, 18:34
against *Moraxella catarrhalis*, 18:34–35
against *Morganella morganii*, 18:35
against *Neisseria gonorrhoeae*, 18:35
against *Proteus mirabilis*, 18:35
against *Staphylococcus aureus*, 18:33
against *Staphylococcus epidermidis*, 18:33

against *Staphylococcus saprophyticus*, 18:33–34

against *Streptococcus agalactiae*, 18:34, 18:65

against *Streptococcus pneumoniae*, 18:34, 18:65

against *Streptococcus pyogenes*, 18:34, 18:65

Cefmetazole, against *Bacteroides fragilis*, 18:235–241

Cefoperazone

- against *Bacteroides fragilis*, 18:193, 18:235–241
- against *Bacteroides thetaiotamicron*, 18:193
- against *Clostridium perfringens*, 18:193
- against *Enterobacter* spp., 18:251–258
- against *Eubacterium lentum*, 18:193
- against *Fusobacterium necrophorum*, 18:194
- against *Fusobacterium nucleatum*, 18:194
- against *Klebsiella* spp., 18:251–258
- against *Peptostreptococcus anaerobius*, 18:193
- against *Pseudomonas aeruginosa*, 18:251–258
- against *Veillonella parvula*, 18:194

Cefoperazone–sulbactam, against *Bacteroides fragilis*, 18:235–241

Cefotaxime

- against *Acinetobacter* spp., 18:61–68
- against *Bacteroides fragilis*, 18:61–68, 18:193, 18:235–241, 20:135–142, 20:213–220
- against *Bacteroides thetaiotamicron*, 18:193
- against *Citrobacter freundii*, 20:49–55
- against *Clostridium perfringens*, 18:193
- against *Clostridium* spp., 20:213–220
- against *Corynebacterium jeikeium*, 20:49–55
- against *Enterobacter cloacae*, 20:49–55
- against *Enterobacteriaceae*, 18:61, 20:143–149
- against enterococci, 18:61–68, 20:49–55
- against *Enterococcus* spp., 20:143–149
- against *Eubacterium lentum*, 18:193
- against *Fusobacterium necrophorum*, 18:194
- against *Fusobacterium nucleatum*, 18:194
- against *Fusobacterium* spp., 20:213–220
- against Gram-negative bacilli, 18:61, 19:111–120
- against Gram-positive cocci, 19:111–120
- against *Haemophilus influenzae*, 18:61–68, 20:49–55, 20:143–149
- against *Lactobacillus* spp., 20:213–220
- against *Mobiluncus* spp., 20:213–220
- against *Moraxella catarrhalis*, 18:61–68, 20:49–55, 20:143–149
- against *Neisseria gonorrhoeae*, 20:49–55
- against *Nocardia* spp., 19:101–110
- against *Peptostreptococcus anaerobius*, 18:193
- against *Peptostreptococcus* spp., 20:213–220
- against pneumococci, 18:61
- against *Prevotella bivia/disiens*, 20:213–220
- against *Prevotella* spp., 20:135–142
- against *Providencia stuartii*, 20:49–55
- against *Pseudomonas aeruginosa*, 18:61–68, 20:49–55, 20:143–149
- against staphylococci, 18:61
- against *Staphylococcus aureus*, 20:49–55

against streptococci, 18:61

against *Streptococcus* spp., 20:49–55

against *Veillonella parvula*, 18:194, 20:135–142

against *Xanthomonas maltophilia*, 18:61–68

Cefotetan

- against *Bacteroides fragilis*, 18:193, 18:235–241
- against *Bacteroides thetaiotamicron*, 18:193
- against *Clostridium perfringens*, 18:193
- against *Eubacterium lentum*, 18:193
- against *Fusobacterium necrophorum*, 18:194
- against *Fusobacterium nucleatum*, 18:194
- against Gram-negative bacilli, 19:111–120
- against Gram-positive cocci, 19:111–120
- against *Peptostreptococcus anaerobius*, 18:193
- against *Veillonella parvula*, 18:194

Cefoxitin

- against *Bacteroides fragilis*, 18:193, 18:235–241, 20:135–142
- against *Bacteroides thetaiotamicron*, 18:193
- against *Clostridium perfringens*, 18:193
- against *Eubacterium lentum*, 18:193
- against *Fusobacterium necrophorum*, 18:194
- against *Fusobacterium nucleatum*, 18:194
- against Gram-negative bacilli, 18:25–30, 19:111–120
- against Gram-positive cocci, 19:111–120
- against *Mycobacterium chelonei*, 19:183–186
- against *Mycobacterium fortuitum*, 19:183–186
- against *Neisseria gonorrhoeae*, 18:177–178
- against *Prevotella* spp., 20:135–142
- against *Veillonella parvula*, 18:194, 20:135–142

Cefpirome

- against *Citrobacter freundii*, 20:49–55
- against *Corynebacterium jeikeium*, 20:49–55
- against *Enterobacter cloacae*, 20:49–55
- against enterococci, 20:49–55
- against *Haemophilus influenzae*, 20:49–55
- against *Moraxella catarrhalis*, 20:49–55
- against *Neisseria gonorrhoeae*, 20:49–55
- against *Providencia stuartii*, 20:49–55
- against *Pseudomonas aeruginosa*, 20:49–55
- against *Staphylococcus aureus*, 20:49–55
- against *Streptococcus* spp., 20:49–55

Cefpodoxime

- against *Staphylococcus aureus*, 18:33
- against *Staphylococcus epidermidis*, 18:33
- against *Staphylococcus saprophyticus*, 18:33–34

Cefpodoxime proxetil

- against *Escherichia coli*, 18:263–265
- against *Haemophilus influenzae*, 18:41–47
- against *Staphylococcus aureus*, 18:41–47

Cefprozil

- against *Citrobacter diversus*, 18:130
- against *Citrobacter freundii*, 18:130
- against *Corynebacterium* spp., 18:130
- against *Enterobacter* spp., 18:129
- against *Enterococcus faecalis*, 18:130
- against *Escherichia coli*, 18:130
- against Gram-negative bacilli, 18:129
- against *Haemophilus influenzae*, 18:129–132
- against *Haemophilus parainfluenzae*, 18:130

against *Klebsiella oxytoca*, 18:130

against *Klebsiella pneumoniae*, 18:130

against *Moraxella catarrhalis*, 18:129–132

against *Proteus mirabilis*, 18:130

against *Serratia marcescens*, 18:130

against *Staphylococcus aureus*, 18:130

against *Staphylococcus epidermidis*, 18:130

against *Staphylococcus haemolyticus*, 18:130

against *Staphylococcus hominis*, 18:130

against *Staphylococcus saprophyticus*, 18:130

against *Streptococcus imitis*, 18:130

against *Streptococcus pneumoniae*, 18:130

against *Streptococcus sanguis*, 18:130

against *Streptococcus* spp., 18:130

Cefquinome (HR 111V)

- against *Citrobacter freundii*, 20:49–55
- against *Corynebacterium jeikeium*, 20:49–55
- against *Enterobacter cloacae*, 20:49–55
- against enterococci, 20:49–55
- against *Haemophilus influenzae*, 20:49–55
- against *Moraxella catarrhalis*, 20:49–55
- against *Neisseria gonorrhoeae*, 20:49–55
- against *Providencia stuartii*, 20:49–55
- against *Pseudomonas aeruginosa*, 20:49–55
- against *Staphylococcus aureus*, 20:49–55
- against *Streptococcus* spp., 20:49–55

Ceftamet pivoxil (CAT), against *Neisseria gonorrhoeae*, 19:121–127

Ceftazidime

- against *Acinetobacter calcoaceticus*, 18:170
- against *Acinetobacter* spp., 18:170, 19:151–156
- against *Aeromonas hydrophila*, 18:170
- against *Bacillus* spp., 18:167–173
- cefepime and, 19:33–38
- against *Citrobacter diversus*, 18:168
- against *Citrobacter freundii*, 18:168, 19:151–156, 20:49–55
- against *Corynebacterium jeikeium*, 20:49–55
- against *Enterobacter aerogenes*, 18:168
- against *Enterobacter cloacae*, 18:168, 19:151–156, 20:49–55
- against *Enterobacteriaceae*, 18:167–173
- against *Enterobacter sakazakii*, 18:168
- against *Enterobacter* spp., 18:167–173, 18:251–258
- against enterococci, 18:167–173, 20:49–55
- against *Enterococcus avium*, 18:171
- against *Enterococcus faecalis*, 18:171, 19:151–156
- against *Enterococcus faecium*, 18:171
- against *Enterococcus* spp., 18:171
- against *Escherichia coli*, 18:168, 19:151–156, 20:203–208
- against *Flavobacterium* spp., 18:167–173
- against Gram-negative bacilli, 18:167–173, 19:111–120, 20:175–179
- against Gram-positive cocci, 18:167–173, 19:111–120
- against *Haemophilus influenzae*, 20:49–55
- against *Klebsiella oxytoca*, 18:168
- against *Klebsiella pneumoniae*, 18:168, 20:203–208
- against *Klebsiella* spp., 18:251–258, 19:151–156
- against *Moraxella catarrhalis*, 20:49–55
- against *Morganella morganii*, 18:168

against *Neisseria gonorrhoeae*, 20:49–55
 against *Proteus mirabilis*, 18:168
 against *Proteus* spp., 19:151–156
 against *Providencia rettgeri*, 18:168
 against *Providencia* spp., 18:167–173
 against *Providencia stuartii*, 20:49–55
 against *Pseudomonas aeruginosa*, 18:167–173, 18:251–258, 19:151–156, 20:49–55
 against *Pseudomonas* spp., 18:167–173
 against *Salmonella* spp., 18:168
 against *Serratia liquefaciens*, 18:167–173
 against *Serratia marcescens*, 18:169, 19:151–156
 against *Serratia* spp., 18:169
 against *Staphylococci*, 18:171, 18:209, 20:175–179
 against *Staphylococcus aureus*, 18:167–173, 19:151–156, 20:49–55, 20:175–179
 against *Staphylococcus epidermidis*, 18:171
 against *Staphylococcus haemolyticus*, 18:171
 against *Staphylococcus hominis*, 18:171
 against *Staphylococcus saprophyticus*, 18:171
 against streptococci, 18:167–173
 against *Streptococcus pneumoniae*, 20:175–179
 against *Streptococcus* spp., 20:49–55
 in US national surveillance study, 19:203–215
 against *Xanthomonas maltophilia*, 18:167–173
 Cefazidime–netilmicin, against *Pseudomonas aeruginosa*, 19:39–46
 Cefazidime–tobramycin, against *Pseudomonas aeruginosa*, 19:39–46
 Ceftrizoxime
 against *Bacteroides fragilis*, 18:193, 18:235–241, 20:135–142
 against *Bacteroides thetaiotamicron*, 18:193
 against *Clostridium perfringens*, 18:193
 against *Eubacterium lenthum*, 18:193
 against *Fusobacterium necrophorum*, 18:194
 against *Fusobacterium nucleatum*, 18:194
 against *Haemophilus influenzae*, 19:65–68
 against *Neisseria gonorrhoeae*, 19:65–68
 against *Peptostreptococcus anaerobius*, 18:193
 against *Prevotella* spp., 20:135–142
 against *Veillonella parvula*, 18:194, 20:135–142
 Ceftriaxone
 against *Aspergillus ureae*, 20:105–107
 against *Bacteroides capillosus*, 19:227–234
 against *Bacteroides fragilis*, 18:193, 18:235–241, 19:227–234, 20:135–142
 against *Bacteroides thetaiotamicron*, 18:193
 against *Clostridium perfringens*, 18:193
 against *Clostridium* spp., 19:227–234
 against *Enterobacteriaceae*, 20:143–149
 against *Enterobacter* spp., 18:251–258
 against *Enterococcus* spp., 20:143–149
 against *Eubacterium lenthum*, 18:193
 against *Eubacterium* spp., 19:227–234
 against *Fusobacterium necrophorum*, 18:194
 against *Fusobacterium nucleatum*, 18:194
 against *Fusobacterium* spp., 19:227–234
 against Gram-negative bacilli, 19:111–120
 against Gram-positive cocci, 19:111–120
 against *Haemophilus influenzae*, 20:143–149
 against *Klebsiella pneumoniae*, 20:203–208
 lactoferrin interaction with *Salmonella* spp. and, 20:69–75
 against *Moraxella catarrhalis*, 20:143–149
 against *Pseudomonas aeruginosa*, 20:143–149
 in US national surveillance study, 19:203–215
 Cell culture
 chlamydial antigen, 18:101–104
 virus survival in, 19:137–142
 Cephalexin
 against *Staphylococcus aureus*, 18:33
 against *Staphylococcus epidermidis*, 18:33
 against *Staphylococcus saprophyticus*, 18:33–34
 Cephalosporins
 against *Bacteroides fragilis*, 18:235–241
 against Gram-negative bacilli, 19:33–38
 against *Haemophilus influenzae*, 18:41–47
 against *Neisseria gonorrhoeae*, 19:121–127
 against *Pseudomonas stutzeri*, 19:51–56
 against *staphylococci*, 18:31–39, 18:65
 against *Staphylococcus aureus*, 18:41–47
 in US national surveillance study, 19:204–215
 Cephamins, against *Bacteroides fragilis*, 18:235–241
 Cerebrospinal fluid (CSF)
 Candida spp. in, 20:33–40
 Sporothrix schenckii in, 18:111–115
 Streptococcus pneumoniae in, 18:211–214, 19:157–161
 Cervical intraepithelial neoplasia (CIN), human papillomavirus in, 18:95–100
 Checkerboard assays, of *Pseudomonas aeruginosa* susceptibility, 19:39–46
 Chemotherapy
 antistaphylococcal, 19:25–31
 strongyloidiasis evaluation after, 18:19–23
Chlamydia pneumoniae, antibody to, 18:229, 230–233
Chlamydia trachomatis
 Amplicor test for, 20:195–201
 automated enzyme-linked fluorescent assay for, 18:101–104
 Chlamidiazyme, with blocking assay, for chlamydial antigen, 18:101–104
 Chloramphenicol
 against *Enterococcus faecium*, 20:42
 against Gram-negative anaerobic rods, 18:25–30
 lactoferrin interaction with *Salmonella* spp. and, 20:69–75
 against *Streptococcus milleri* group, 19:70–73
 Chocolate–Mueller–Hinton agar, *Neisseria gonorrhoeae* on, 18:175
 Chromosomes, in *Mycobacterium tuberculosis*, 18:215–218
 CI-960, against *Enterococcus faecium*, 20:42
 Cigarette smoking, human papillomavirus risk and, 18:95–100
 Cilofungin (LY121019), against *Candida* spp., 18:89–94
 CIN. See Cervical intraepithelial neoplasia
 Ciprofloxacin
 against *Acinetobacter* spp., 18:50–56, 18:61–68, 19:151–156
 against anaerobic bacteria, 19:129–133
 against *Bacteroides fragilis*, 18:61–68, 19:129–133, 19:235–243
 cefepime and, 19:33–38
 against *Citrobacter diversus*, 19:235–243
 against *Citrobacter freundii*, 19:151–156, 19:235–243
 against *Corynebacterium* spp., 19:171–173
 in disk diffusion tests, 18:125–127
 against *Enterobacter aerogenes*, 19:235–243
 against *Enterobacter cloacae*, 19:151–156, 19:235–243
 against *Enterobacteriaceae*, 18:61, 19:235–243
 against *Enterobacter* spp., 18:251–258
 against enterococci, 18:61
 against *Enterococcus faecalis*, 19:151–156, 19:235–243
 against *Enterococcus faecium*, 20:42
 against *Enterococcus* spp., 18:50–56
 against *Escherichia coli*, 19:151–156, 19:235–243, 20:45–47

against Gram-negative bacilli, 18:61, 18:181–189, 19:111–120
 against Gram-positive cocci, 18:50–56, 19:111–120
 against *Haemophilus influenzae*, 18:61–68
 against *Helicobacter pylori*, 19:235–243
 against *Klebsiella oxytoca*, 19:235–243
 against *Klebsiella pneumoniae*, 19:235–243
 against *Klebsiella* spp., 18:251–258, 19:151–156
 lactoferrin interaction with *Salmonella* spp. and, 20:69–75
 against *Listeria monocytogenes*, 20:21–25
 against *Moraxella catarrhalis*, 18:61–68
 against *Morganella morganii*, 19:235–243
 against *Mycobacterium avium-intracellulare*, 19:179–181
 against *Mycobacterium chelonae*, 19:183–186
 against *Mycobacterium fortuitum*, 19:183–186
 against *Mycobacterium genavense*, 18:10
 against *Nocardia* spp., 19:101–110
 ofloxacin and, 18:49–56
 against pneumococci, 18:61
 against *Proteus* spp., 19:151–156
 against *Pseudomonas aeruginosa*, 18:61–68, 18:251–258, 19:151–156, 19:235–243
 against *Salmonella* spp., 20:46
 against *Salmonella typhi*, 20:46
 against *Serratia marcescens*, 19:151–156, 19:235–243
 against *Shigella* spp., 20:46
 against staphylococci, 18:50–56, 18:61, 19:143–147, 19:235–243
 against *Staphylococcus aureus*, 19:143–147, 19:151–156
 against streptococci, 18:61
 against *Streptococcus pneumoniae*, 19:235–243
 against *Streptococcus pyogenes*, 19:235–243
 in US national surveillance study, 19:203–215
 against *Xanthomonas maltophilia*, 18:61–68
 Citrate-anticoagulated whole blood, *Streptococcus pneumoniae* and, 20:187–193
Citrobacter diversus
 amoxicillin-clavulanate against, 18:183
 cefaclor against, 18:130, 18:163
 cefepime against, 18:168
 cefixime against, 18:183
 cefprozil against, 18:130
 ceftazidime against, 18:168
 cefuroxime against, 18:183
 ciprofloxacin against, 18:183, 19:235–243
 CP-99,219 against, 19:235–243
 FK-307 against, 18:168
 fleroxacin against, 18:183
 lomefloxacin against, 18:183
 ofloxacin against, 18:183
 sparflloxacin against, 19:235–243
 trimethoprim-sulfamethoxazole against, 18:183
Citrobacter freundii
 amikacin against, 19:151–156
 amoxicillin-clavulanate against, 18:183
 cefaclor against, 18:130, 18:183
 cefepime against, 18:168, 19:35, 20:49–55
 cefixime against, 18:183
 cefprozil against, 18:130
 ceftazidime against, 18:168, 19:151–156
 cefotaxime against, 20:49–55
 cefpirome against, 20:49–55
 cefquinome against, 20:49–55
 ceftazidime against, 20:49–55
 cefuroxime against, 18:183
 ciprofloxacin against, 18:183, 19:151–156, 19:235–243
 CP-99,219 against, 19:235–243
 FK-307 against, 18:168
 fleroxacin against, 18:183
 gentamicin against, 19:151–156
 imipenem against, 19:151–156
 lomefloxacin against, 18:183, 20:93–98
 ofloxacin against, 18:183
 piperacillin against, 19:151–156
 piperacillin-tazobactam against, 19:151–156
 sparflloxacin against, 19:235–243
 ticarcillin-clavulanate against, 19:151–156
 trimethoprim-sulfamethoxazole against, 18:183
Citrobacter spp., in Lebanese antimicrobial susceptibility study, 20:151–158
Clal, in ribotyping *Pseudomonas cepacia*, 20:181–186
Clarithromycin
 against *Haemophilus influenzae*, 18:243–249
 against *Mycobacterium genavense*, 18:10
Clindamycin
 against anaerobic bacteria, 19:129–133
 against *Bacteroides fragilis*, 18:235–241, 19:129–133, 20:213–220
 against *Clostridium* spp., 20:213–220
 against *Fusobacterium* spp., 20:213–220
 against Gram-negative anaerobic rods, 18:25–30
 against *Lactobacillus* spp., 20:213–220
 against *Legionella* spp., 19:175–178
 against *Mobiluncus* spp., 20:213–220
 against *Peptostreptococcus* spp., 20:213–220
 against *Prevotella bivia/disiens*, 20:213–220
 against *Streptococcus milleri* group, 19:70–73
Clofazimine, against *Mycobacterium genavense*, 18:10
Clostridium difficile
 Bartels Prima System Toxin enzyme immunoassay for, 20:1–5
 FK-307 against, 20:27–32
 TechLab Tox-A enzyme immunoassay for, 20:1–5
 toxins A and B, IgG against, 18:205–209
Clostridium spp.
 amoxicillin-clavulanate against, 19:227–234
 ampicillin-sulbactam against, 19:227–234, 20:213–220
 cefotaxime against, 20:135–142, 20:213–220
 cefoxitin against, 20:135–142
 ceftizoxime against, 20:135–142
 ceftriaxone against, 19:227–234, 20:135–142
Corynebacterium jeikeium
 ampicillin against, 19:171–173
 cefepime against, 20:49–55
 cefotaxime against, 20:49–55
 cefpirome against, 20:49–55
 cefquinome against, 20:49–55
 ceftazidime against, 20:49–55
 ciprofloxacin against, 19:171–173
 doxycycline against, 19:171–173
 erythromycin against, 19:171–173
 gentamicin against, 19:171–173
 vancomycin against, 19:171–173
Corynebacterium spp.
 cefaclor against, 18:130
 cefprozil against, 18:130
 ciprofloxacin against, 19:171–173
 doxycycline against, 19:171–173
 erythromycin against, 19:171–173
 gentamicin against, 19:171–173
 vancomycin against, 19:171–173
Corynebacterium urealyticum
 ampicillin against, 19:171–173
 ciprofloxacin against, 19:171–173
 doxycycline against, 19:171–173
 erythromycin against, 19:171–173
 gentamicin against, 19:171–173
 vancomycin against, 19:171–173
CP-99,219
 against *Bacteroides fragilis*, 19:235–243
 broth microdilution testing for, 20:167–170
 against *Citrobacter diversus*, 19:235–243
 against *Citrobacter freundii*, 19:235–243

disk diffusion testing for, 20:167–170
 against *Enterobacter aerogenes*, 19:235–243
 against *Enterobacter cloacae*, 19:235–243
 against *Enterobacteriaceae*, 19:235–243
 against *Enterococcus faecalis*, 19:235–243
 against *Escherichia coli*, 19:235–243
 against *Helicobacter pylori*, 19:235–243
 against *Klebsiella oxytoca*, 19:235–243
 against *Klebsiella pneumoniae*, 19:235–243
 against *Morganella morganii*, 19:235–243
 against *Pseudomonas aeruginosa*, 19:235–243
 against *Serratia marcescens*, 19:235–243
 against staphylococci, 19:235–243
 against *Streptococcus pneumoniae*, 19:235–243
 against *Streptococcus pyogenes*, 19:235–243
C polysaccharide, for detection of *Streptococcus pneumoniae*, 18:211–214
Cryptococcus neoformans
 amphotericin B against, 19:10
 fluconazole against, 19:10, 19:218–219, 20:81–91
 5-fluorocytosine against, 19:10, 19:218–219
Cryptosporidium spp.
 enzyme-linked immunosorbent assays for, 19:221–225
 Merifluor immunofluorescent assay for, 19:89–91
CSF. *See* Cerebrospinal fluid
 Cutaneous sporotrichosis, in AIDS, 18:111–116
Cyclospora sp., in diarrhea, 19:47–49
 Cystic fibrosis, *Pseudomonas cepacia* in, 20:181–186
 Cytomegalovirus (CMV)
 enzyme immunoassays for, 20:109–112
 latex agglutination tests for, 20:109–112
 in peripheral blood leukocytes, 19:15–18
 polymerase chain reaction for, 20:13–19

D0870
 against *Candida* spp., 19:75–80
 against *Torulopsis glabrata*, 19:75–80
 Daptomycin, against *Enterococcus faecium*, 20:42
DFA. *See* Direct fluorescent antibody
 Dialysis, *Aspergillus* and, 20:99–103
 Diamedix enzyme immunoassay, for cytomegalovirus antibody, 20:109–112
 Diarrhea
Clostridium difficile in, 18:205–209
Cyclospora sp. in, 19:47–49
 Digoxigenin-labeled probe, for cytomegalovirus, 20:13–19
 Direct fluorescent antibody (DFA), in detection of chlamydial antigen, 18:101–104
 Direct slide agglutination test, of *Shigella dysenteriae* serotype 13, 18:145–149
 Dirithromycin
 against *Mycoplasma hominis*, 20:57–59
 against *Mycoplasma pneumoniae*, 20:57–59
 against *Ureaplasma urealyticum*, 20:57–59
 Disk approximation synergy test, for extended-spectrum β -lactamases, 20:203–208

Disk diffusion susceptibility testing
 CP-99219 in, 20:167–170
 DU-6859a in, 18:125–127
 for *Haemophilus influenzae*, 18:243–249
 for *Neisseria gonorrhoeae*, 18:175
 for *Nocardia* spp., 19:101–110
 DNA amplification
 in *Mycobacterium* spp., 18:13–18
 in *Nocardia* spp., 18:13–18
 in *Pneumocystis carinii*, 18:197–199
 DNA probes, acridinium-ester-labeled, 18:137–139
 DNA sequencing, of rifampin resistance locus, 18:219–227
 Dot-blot hybridization
 for cytomegalovirus, 20:13–19
 for human papillomavirus, 18:95–100
 Doxycycline
 against *Corynebacterium* spp., 19:171–173
 against *Enterococcus faecium*, 20:41–43
 against *Legionella* spp., 19:175–178
 against *Mycobacterium chelonae*, 19:183–186
 against *Mycobacterium fortuitum*, 19:183–186
 Drop inoculation, for methicillin-resistant *Staphylococcus aureus*, 18:121–124
DU-6859a
 against *Acinetobacter* spp., 18:125
 against *Campylobacter* spp., 20:45–47
 in disk diffusion tests, 18:125–127
 against *Enterobacteriaceae*, 18:125
 against enterococci, 18:125
 against *Enterococcus faecalis*, 19:65–68
 against *Escherichia coli*, 18:57–59, 20:45–47
 against *Haemophilus influenzae*, 19:93–99
 against *Moraxella catarrhalis*, 18:126
 against *Pseudomonas aeruginosa*, 19:65–68
 against *Pseudomonas* spp., 18:125
 against *Salmonella* spp., 20:46
 against *Salmonella typhi*, 20:46
 against *Shigella* spp., 20:46
 against staphylococci, 18:125
 against *Staphylococcus aureus*, 18:57–59, 19:65–68
 against *Xanthomonas maltophilia*, 18:125
EcoRI, in ribotyping *Pseudomonas cepacia*, 20:181–186
EDTA, *Streptococcus pneumoniae* and, 20:187–193
EIA. *See* Enzyme immunoassay
Electron microscopy (EM), of adenoviruses, 18:157–159, 18:161–166
Electrophoretic karyotyping, of *Candida lusitaniae*, 20:127–133
ELFA. *See* Enzyme-linked fluorescent assay
ELISA. *See* Enzyme-linked immunosorbent assay
EM. *See* Electron microscopy
Endocervical specimens, *Chlamydia trachomatis* in, 20:195–201
Enhanced chemiluminescence, in detection of human papillomavirus, 18:95–100
Enoxacin, against *Staphylococcus aureus*, 19:143–147
Enteric tract
 adenoviruses in, 18:161–166
Enterococcus faecium in, 18:105–109

Enterobacter aerogenes
 amoxicillin-clavulanate against, 18:183
 cefaclor against, 18:183
 cefepime against, 18:168
 cefixime against, 18:183
 cefazidime against, 18:168
 cefuroxime against, 18:183
 ciprofloxacin against, 18:183, 19:235–243
 CP-99,219 against, 19:235–243
 FK-037 against, 18:168
 fleroxacin against, 18:183
 lomefloxacin against, 18:183
 ofloxacin against, 18:183
 sparfloxacin against, 19:235–243
 trimethoprim-sulfamethoxazole against, 18:183
Enterobacter agglomerans
 amoxicillin-clavulanate against, 18:183
 cefaclor against, 18:183
 cefixime against, 18:183
 cefuroxime against, 18:183
 ciprofloxacin against, 18:183
 fleroxacin against, 18:183
 lomefloxacin against, 18:183
 ofloxacin against, 18:183
 trimethoprim-sulfamethoxazole against, 18:183
Enterobacter cloacae
 amoxicillin-clavulanate against, 18:183
 cefaclor against, 18:183
 cefepime against, 18:168, 19:33–38, 20:49–55
 cefixime against, 18:183
 cefotaxime against, 20:49–55
 cefpirome against, 20:49–55
 cefquinome against, 20:49–55
 cefazidime against, 18:168, 20:49–55
 cefuroxime against, 18:183
 ciprofloxacin against, 18:183, 19:235–243
 CP-99,219 against, 19:235–243
 FK-037 against, 18:168
 fleroxacin against, 18:183
 lomefloxacin against, 18:183
 ofloxacin against, 18:183
 sparfloxacin against, 19:235–243
 in spontaneous bacterial peritonitis, 19:3
 trimethoprim-sulfamethoxazole against, 18:183
Enterobacteriaceae
 ampicillin against, 20:143–149
 ampicillin-sulbactam against, 20:143–149
 β -lactamase-producing, 20:203–208
 cefepime against, 18:167–173, 19:33–38
 cefotaxime against, 18:61, 20:143–149
 cefazidime against, 18:167–173
 ceftriaxone against, 20:143–149
 cefuroxime against, 20:143–149
 ciprofloxacin against, 18:61, 19:235–243
 CP-99,219 against, 19:235–243
 DU-6859a against, 18:125
 FK-037 against, 18:167–173
 oxacillin against, 20:143–149
 piperacillin against, 20:143–149
 piperacillin-tazobactam against, 20:143–149
 Ro 23-9424 against, 18:61
 Ro 25-0534 against, 18:61
 sparfloxacin against, 19:235–243

in US national surveillance study, 19: 204-215

Enterobacter sakazakii
cefepime against, 18:168
ceftazidime against, 18:168
FK-037 against, 18:168

Enterobacter spp.
aztreonam against, 18:251-258
Bauer-Kirby disk diffusion for, 18:251-258
cefaclor against, 18:129
cefepime against, 18:167-173, 19:33-35
cefoperazone against, 18:251-258
cefprozil against, 18:129
ceftazidime against, 18:167-173, 18:251-258
ceftriaxone against, 18:251-258
ciprofloxacin against, 18:251-258
FK-037 against, 18:167-173, 20:27-32
gentamicin against, 18:251-258
imipenem against, 18:251-258
in Lebanese antimicrobial susceptibility study, 20:151-158
piperacillin against, 18:251-258
serial plate agar dilution for, 18:251-258
ticarcillin-clavulanic acid against, 18:251-258
tobramycin against, 18:251-258
Vitek AutoMicrobic system for, 18:251-258

Enterococci
aminoglycosides against, 20:61-67
ampicillin against, 19:57-60, 20:61-67
cefepime against, 18:167-173, 20:49-55
cefotaxime against, 18:61, 20:49-55
cefprome against, 20:49-55
cefquinome against, 20:49-55
ceftazidime against, 18:167-173, 18:205, 20:49-55
ciprofloxacin against, 18:61
DU-6859a against, 18:125
FK-037 against, 18:167-173
gentamicin against, 19:57-60, 20:61-67
kanamycin against, 20:61-67
penicillin against, 19:57-60
penicillin-aminoglycosides against, 19: 57-60
Ro 23-9424 against, 18:61
Ro 25-0534 against, 18:61
streptomycin against, 20:61-67
in US national surveillance study, 19: 203-215
vancomycin against, 20:61-67, 113-116

Enterococcus avium
cefepime against, 18:171
ceftazidime against, 18:171
FK-037 against, 18:171

Enterococcus faecalis
amikacin against, 19:151-156
amoxicillin-clavulanate against, 18:187
biapenem against, 19:65-68
cefaclor against, 18:130, 18:187
cefdinir against, 18:31-39
cefepime against, 18:171
cefixime against, 18:187
cefprozil against, 18:130
ceftazidime against, 18:171, 19:151-156
cefuroxime against, 18:187

ciprofloxacin against, 18:187, 19:151-156, 19:235-243
CP-99,219 against, 19:235-243
DU-6859a against, 19:65-68
FK-037 against, 18:171, 19:65-68
fleroxacin against, 18:187
gentamicin against, 19:151-156
grepafloxacin against, 19:65-68
imipenem against, 19:151-156
levofloxacin against, 19:65-68
lomefloxacin against, 18:187
molecular epidemiology of, 19:197-202
ofloxacin against, 18:187
piperacillin against, 19:151-156
piperacillin-tazobactam against, 19:151-156
sparfloxacin against, 19:235-243
in spontaneous bacterial peritonitis, 19: 1-4
ticarcillin-clavulanic acid against, 19:151-156
trimethoprim-sulfamethoxazole against, 18:187

Enterococcus faecium
aminoglycosides against, 20:41-43
amoxicillin-clavulanate against, 18:188, 20:42
ampicillin against, 18:105-109, 20:41-43
bacitracin against, 18:105-109
cefaclor against, 18:188
cefepime against, 18:171
cefixime against, 18:188
ceftazidime against, 18:171
cefuroxime against, 18:188
chloramphenicol against, 20:42
CI-960 against, 20:42
ciprofloxacin against, 18:187, 20:42
daptomycin against, 20:42
doxycycline against, 20:41-43
erythromycin against, 20:42
FK-037 against, 18:171
fleroxacin against, 18:187
gentamicin against, 20:42
lomefloxacin against, 18:188
macrolides against, 20:41-43
ofloxacin against, 18:188, 20:42
piperacillin against, 20:42
quinolones against, 20:41-43
rifampin against, 20:42
RP59,500 against, 20:42
sparfloxacin against, 20:42
streptomycin against, 20:42
teicoplanin against, 20:42
tetracycline against, 20:42
trimethoprim-sulfamethoxazole against, 18:188
in US national surveillance study, 19: 204-215
vancomycin against, 18:105-109, 20:41-43

Enterococcus spp.
amoxicillin-clavulanate against, 18:188
ampicillin against, 20:143-149
ampicillin-sulbactam against, 20:143-149
cefaclor against, 18:188
cefepime against, 18:171
cefixime against, 18:188
cefotaxime against, 20:143-149

ceftazidime against, 18:171
ceftriaxone against, 20:143-149
cefuroxime against, 18:188, 20:143-149
ciprofloxacin against, 18:50-56, 18:188
FK-037 against, 18:171
fleroxacin against, 18:188
lomefloxacin against, 18:188
ofloxacin against, 18:50-56, 18:188
oxacillin against, 20:143-149
piperacillin against, 20:143-149
piperacillin-tazobactam against, 20:143-149
trimethoprim-sulfamethoxazole against, 18:188

Enzyme immunoassay (EIA)
for adenoviruses, 18:161-166
for *Chlamydia trachomatis*, 20:195-201
for *Clostridium difficile*, 20:1-5
for *Cryptosporidium* spp., 19:221-225
for cytomegalovirus antibody, 20:109-112
for *Toxoplasma*-specific IgG, 19:19-24

Enzyme-linked fluorescent assay (ELFA)
automated, of chlamydial antigen, 18: 101-104
of *Toxoplasma*-specific IgG, 19:19-24

Enzyme-linked immunosorbent assay (ELISA)
of adenoviruses, 18:157-159
of *Clostridium difficile*, 18:205-209
for postchemotherapy evaluation of strongyloidiasis, 18:19-23

Erythromycin
against *Corynebacterium* spp., 19:171-173
against *Enterococcus faecium*, 20:42
against Gram-negative bacilli, 18:181-189
against *Haemophilus influenzae*, 18:243-249
lactoferrin interaction with *Salmonella* spp. and, 20:69-75
against *Legionella* spp., 19:175-178
mecA gene and, 19:25-31
against *Mycoplasma hominis*, 20:57-59
against *Mycoplasma pneumoniae*, 20:57-59
against *Streptococcus milleri* group, 19:70-73
against *Ureaplasma urealyticum*, 20:57-59
in US national surveillance study, 19: 204-215

Escherichia coli
amikacin against, 19:151-156
amoxicillin-clavulanate against, 18:183
amoxicillin-clavulanic acid against, 18: 263-265
cefaclor against, 18:130, 18:183
cefdinir against, 18:31-39
cefepime against, 18:168
cefixime against, 18:183
cefpodoxime proxetil against, 18:263-265
cefprozil against, 18:130
ceftazidime against, 18:168, 19:151-156, 20:203-208
cefuroxime against, 18:183, 20:203-208
ciprofloxacin against, 18:183, 19:151-156, 19:235-243, 20:45-47
CP-99,219 against, 19:235-243
DU-6859a against, 18:57-59, 20:45-47
FK-037 against, 18:168, 20:27-32
fleroxacin against, 18:188
gentamicin against, 19:151-156, 20:203-208

imipenem against, 19:151–156
in Lebanese antimicrobial susceptibility study, 20:151–158
levofloxacin against, 18:57–59
lomefloxacin against, 18:183
monoclonal antibodies specific for *Shigella dysenteriae* serotype 13 and, 18:145–149
ofloxacin against, 18:57–59, 18:183, 20:203–208
piperacillin against, 19:151–156
piperacillin–tazobactam against, 19:151–156
ribotyping and, 18:263–265
sparfloxacin against, 19:235–243
in spontaneous bacterial peritonitis, 19:3
Streptococcus pneumoniae and, 20:187–193
ticarcillin–clavulanic acid against, 19:151–156
trimethoprim–sulfamethoxazole against, 18:183
in US national surveillance study, 19:203–215
Esophagitis, *Candida* spp. in, 18:89–94
Etest
for anaerobe susceptibility testing, 18:25–30
for antifungal susceptibility testing, 19:217–220
for bacterial vaginosis and peritonitis, 20:213–220
for *Corynebacterium* spp., 19:171–173
inoculum effects on, 19:163–166
kill curves and, 19:187–195
for *Legionella pneumophila*, 20:159–162
for *Legionella* spp., 19:175–178
for methicillin-resistant staphylococci, 19:167–170
minimum bactericidal concentrations and, 19:187–195
for *Mycobacterium avium*–*intracellulare*, 19:179–181
for *Mycobacterium chelonae*, 19:183–186
for *Mycobacterium fortuitum*, 19:183–186
for *Mycobacterium tuberculosis*, 19:179–181
for *Nocardia* spp., 19:101–110
for penicillin resistance among *Streptococcus pneumoniae*, 19:157–161
postantibiotic effects and, 19:187–195
for resistance epidemiology, 19:151–156
Ethambutol, against *Mycobacterium genavense*, 18:10
Eubacterium spp.
amoxicillin–clavulanate against, 19:227–234
ampicillin–sulbactam against, 19:227–234
cefotaxime against, 20:135–142
cefoxitin against, 20:135–142
ceftizoxime against, 20:135–142
ceftriaxone against, 19:227–234, 20:135–142
ceftriaxone–tazobactam against, 19:227–234
metronidazole against, 19:227–234, 20:135–142
piperacillin against, 20:135–142
piperacillin–tazobactam against, 19:227–234
tazobactam against, 19:227–234
ticarcillin–clavulanate against, 19:227–234
Extragenital infections, *Mobiluncus mulieris* in, 20:163–165
5-FC. *See* 5-Fluorocytosine
Fatty acids, in mycobacteria, 19:81–88
Fiberoptic bronchoscopic examinations, for *Coccidioides immitis*, 18:83–87
FK-037
against *Acinetobacter calcoaceticus*, 18:170
against *Acinetobacter* spp., 18:170, 20:27–32
against *Aeromonas hydrophila*, 18:170
against *Aeromonas* spp., 20:27–32
against *Bacillus* spp., 18:167–173
against *Citrobacter diversus*, 18:168
against *Citrobacter freundii*, 18:168, 20:27–32
against *Enterobacter aerogenes*, 18:168
against *Enterobacter cloacae*, 18:168
against *Enterobacteriaceae*, 18:167–173
against *Enterobacter sakazakii*, 18:168
against *Enterobacter* spp., 18:167–173, 20:27–32
against enterococci, 18:167–173
against *Enterococcus avium*, 18:171
against *Enterococcus faecalis*, 18:171, 19:65–68
against *Enterococcus faecium*, 18:171
against *Enterococcus* spp., 18:171
against *Escherichia coli*, 18:168, 20:27–32
against *Flavobacterium* spp., 18:167–173
against Gram-negative bacilli, 18:167–173, 20:175–179
against Gram-positive cocci, 18:167–173
against *Haemophilus influenzae*, 19:65–68, 20:27–32
against *Klebsiella oxytoca*, 18:168
against *Klebsiella pneumoniae*, 18:168
against *Klebsiella* spp., 20:27–32
against *Morganella morganii*, 18:168, 20:27–32
against *Neisseria gonorrhoeae*, 19:65–68, 19:93–99
against *Proteus mirabilis*, 18:168, 20:27–32
against *Proteus vulgaris*, 18:168, 20:27–32
against *Providencia rettgeri*, 18:168
against *Providencia* spp., 18:167–173
against *Providencia stuartii*, 20:27–32
against *Pseudomonas aeruginosa*, 18:167–173, 19:65–68
against *Pseudomonas* spp., 18:167–173, 20:27–32
against *Salmonella* spp., 18:168
against *Salmonella typhi*, 20:27–32
against *Serratia liquefaciens*, 18:167–173
against *Serratia marcescens*, 18:169, 20:27–32
against *Serratia* spp., 18:169
against *Shigella sonnei*, 20:27–32
against staphylococci, 18:171, 20:175–179
against *Staphylococcus aureus*, 18:167–173, 18:205, 19:65–68, 20:27–32, 20:175–179
against *Staphylococcus epidermidis*, 18:171
against *Staphylococcus haemolyticus*, 18:171
against *Staphylococcus hominis*, 18:171, 18:205
against *Staphylococcus saprophyticus*, 18:171, 18:209
against streptococci, 18:167–173
against *Streptococcus pneumoniae*, 20:175–179
against *Xanthomonas maltophilia*, 18:167–173, 20:27–32
against *Yersinia enterocolitica*, 20:27–32
FK482. *See* Cefdinir
Flavobacterium spp.
cefepime against, 18:167–173
ceftazidime against, 18:167–173
FK-037 against, 18:167–173
Fleroxacin
against anaerobic bacteria, 19:129–133
against *Bacteroides fragilis*, 19:129–133
against Gram-negative bacilli, 18:181–189
in US national surveillance study, 19:204–215
Fluconazole
against *Candida albicans*, 19:218–219
against *Candida krusei*, 19:218–219
against *Candida lusitaniae*, 19:219, 20:127–133
against *Candida parapsilosis*, 19:218–219
against *Candida* spp., 19:75–80, 20:81–91
against *Candida tropicalis*, 19:218–219
against *Cryptococcus neoformans*, 19:218–219, 20:81–91
against *Torulopsis glabrata*, 19:75–80, 19:218–219
against yeasts, 19:9–13, 19:217–220
5-Fluorocytosine (5-FC)
against *Candida albicans*, 19:218–219
against *Candida krusei*, 19:218–219
against *Candida lusitaniae*, 19:219, 20:127–133
against *Candida parapsilosis*, 19:218–219
against *Candida* spp., 18:89–94, 19:75–80
against *Candida tropicalis*, 19:218–219
against *Cryptococcus neoformans*, 19:218–219
against *Torulopsis glabrata*, 19:75–80, 19:218–219
against yeasts, 19:9–13, 19:217–220
Fluoroquinolones
comparative susceptibility of, 18:49–56
in disk diffusion tests, 18:125–127
against *Escherichia coli*, 20:45–47
against Gram-negative bacilli, 18:181–189
against *Listeria monocytogenes*, 20:21–25
staphylococcal resistance to, 19:143–147
in US national surveillance study, 19:204–215
Folate antagonists, against *Mycobacterium* spp., 18:201–204
Foreign body removal, *Oerskovia xanthineolytica* and, 18:259–261
Formalin–ether concentration, for *Cryptosporidium* and *Giardia*, 19:89–91
Four-enzyme ribotyping, of *Pseudomonas cepacia*, 20:181–186
Fungemia, *Candida* spp. in, 18:89–94
Fusobacterium spp.
amoxicillin–clavulanate against, 18:18:25–30, 19:227–234
ampicillin against, 18:25–30
ampicillin–sulbactam against, 19:227–234, 20:213–220

cefotaxime against, 20:213–220
 cefoxitin against, 18:25–30
 ceftriaxone against, 19:227–234
 ceftriaxone–tazobactam against, 19:227–234
 chloramphenicol against, 18:25–30
 clindamycin against, 18:25–30, 20:213–220
 imipenem against, 20:213–220
 metronidazole against, 19:227–234
 piperacillin against, 18:25–30
 piperacillin–tazobactam against, 18:25–30, 19:227–234
 tazobactam against, 19:227–234
 ticarcillin against, 18:25–30
 ticarcillin–clavulanate against, 18:25–30, 19:227–234

Gas-liquid chromatography, computer-aided, for mycobacteria, 19:81–88
 Gastric colonization, of *Enterococcus faecalis*, 19:197–202
 Gastrotomy, *Candida* spp. and, 20:33–40
 GC agar
 for DU-6859a and FK-307 susceptibility testing, 19:93–99
 Neisseria gonorrhoeae on, 18:175
 Genetic locus, encoding resistance to rifampin, 18:219–227
 Genital tract infection isolates
 ciprofloxacin against, 18:49–56
 ofloxacin against, 18:49–56
 Genomic DNA
 Candida lusitaniae, 20:127–133
 Enterococcus faecalis, 19:197–202
 Streptococcus pneumoniae, 20:187–193
 Gen-Probe tests, for mycobacteria, 18:137–139
 Gentamicin
 against *Acinetobacter* spp., 19:151–156
 against *Citrobacter freundii*, 19:151–156
 against *Corynebacterium* spp., 19:171–173
 against *Enterobacter cloacae*, 19:151–156
 against *Enterobacter* spp., 18:251–258
 against enterococci, 19:57–60, 20:61–67
 against *Enterococcus faecalis*, 19:151–156
 against *Enterococcus faecium*, 20:42
 against *Escherichia coli*, 19:151–156, 20:203–208
 against *Klebsiella pneumoniae*, 20:203–208
 against *Klebsiella* spp., 18:251–258, 19:151–156
 lactoferrin interaction with *Salmonella* spp. and, 20:69–75
 mecA gene and, 19:25–31
 against *Proteus* spp., 19:151–156
 against *Pseudomonas aeruginosa*, 18:134, 18:251–258, 19:151–156
 against *Serratia marcescens*, 19:151–156
 against *Staphylococcus aureus*, 19:151–156
 in US national surveillance study, 19:204–215
Giardia spp., Merifluor immunofluorescent assay for, 19:89–91
 Giemsa-stained smears, of *Pneumocystis carinii*-containing specimens, 18:197–199
 Gonorrhea, ceftamet pivoxil against, 19:121–127

Graham 293 cells, adenoviruses grown in, 18:161–166
 Gram-negative bacilli
 amikacin against, 20:175–179
 amoxicillin–clavulanate against, 18:25–30
 ampicillin against, 18:25–30
 Bauer–Kirby disk diffusion for, 18:251–258
 cefaclor against, 18:129
 cefepime against, 18:167–173, 19:33–38
 ceftazidime against, 20:175–179
 cefotaxime against, 18:61
 cefoxitin against, 18:25–30
 cefprozil against, 18:129
 ceftazidime against, 18:167–173
 chloramphenicol against, 18:25–30
 ciprofloxacin against, 18:61
 clindamycin against, 18:25–30
 FK-037 against, 18:167–173, 20:175–179
 fluoroquinolones against, 18:181
 imipenem against, 20:175–179
 piperacillin against, 18:25–30
 piperacillin–tazobactam against, 18:25–30
 Ro 23-9424 against, 18:61
 Ro 25-0534 against, 18:61
 serial plate agar dilution for, 18:251–258
 in spontaneous bacterial peritonitis, 19:1–4
 ticarcillin against, 18:25–30
 ticarcillin–clavulanate against, 18:25–30
 in US national surveillance study, 19:204–215
 Vi-specific latex agglutination for, 18:75–78
 Vitek AutoMicrobic system for, 18:251–258

Gram-positive cocci
 cefaclor against, 18:129
 cefepime against, 18:167–173
 cefprozil against, 18:129
 ceftazidime against, 18:167–173
 ciprofloxacin against, 18:50–56
 FK-037 against, 18:167–173
 fluoroquinolones against, 18:181–189
 ofloxacin against, 18:50–56
 in spontaneous bacterial peritonitis, 19:3
 in US national surveillance study, 19:204–215

Gram stains, for detecting false-positive BACTEC blood culture bottles, 20:121–125

Grepafloxacin (OPC-17116)
 against anaerobic bacteria, 19:129–133
 against *Bacteroides fragilis*, 19:129–133
 against *Enterococcus faecalis*, 19:65–68
 against *Haemophilus influenzae*, 19:65–68
 against *Neisseria gonorrhoeae*, 19:65–68
 against *Pseudomonas aeruginosa*, 19:65–68
 against *Staphylococcus aureus*, 19:65–68
 groEL gene, in mycobacteria and nocardiae, 18:13–18
 gyrA gene, in oxacillin resistance in *Staphylococcus aureus*, 19:25–31

Hae III digestion, of *Mycobacterium* and *Nocardia* *groEL* gene, 18:13–18

Haemophilus influenzae
 ampicillin against, 18:41–47, 20:143–149
 ampicillin–sulbactam against, 20:143–149
 amoxicillin–clavulanate against, 18:186
 azithromycin against, 18:243–249
 cefaclor against, 18:41–47, 18:129–132, 18:186
 cefdinir against, 18:31–47
 cefepime against, 20:49–55
 cefixime against, 18:186
 cefotaxime against, 18:61–68, 20:49–55, 20:143–149
 cefpiprome against, 20:49–55
 cefprodoxime proxetil against, 18:41–47
 cefprozil against, 18:129–132
 cefquinome against, 20:49–55
 ceftazidime against, 20:49–55
 ceftizoxime against, 19:65–68
 ceftriaxone against, 20:143–149
 cefuroxime against, 18:186, 20:143–149
 ciprofloxacin against, 18:61–68, 18:186
 clarithromycin against, 18:243–249
 DU-6859a against, 19:93–99
 erythromycin against, 18:243–249
 FK-037 against, 19:65–68, 20:27–32
 fleroxacin against, 18:186
 grepafloxacin against, 19:65–68
 Haemophilus test medium for, 18:243–249
 in Lebanese antimicrobial susceptibility study, 20:151–158
 levofloxacin against, 19:65–68
 lomefloxacin against, 18:186
 ofloxacin against, 18:186
 oxacillin against, 20:143–149
 piperacillin against, 20:143–149
 piperacillin–tazobactam against, 20:143–149
 Ro 23-9424 against, 18:61–68
 Ro 25-0534 against, 18:61–68
 Streptococcus pneumoniae and, 20:187–193
 trimethoprim–sulfamethoxazole against, 18:186
 Haemophilus parainfluenzae
 cefaclor against, 18:130
 cefprozil against, 18:130
 Haemophilus test medium, for *Haemophilus influenzae*, 18:243–249, 19:93–99
Hafnia alvei, cefepime against, 19:35
Helicobacter pylori
 ciprofloxacin against, 19:235–243
 CP-99,219 against, 19:235–243
 rapid urease test systems for, 18:69–74
 sparfloxacin against, 19:235–243
 Hep-2 cells, adenoviruses grown in, 18:161–166
 Hepatic abscesses, *Streptococcus intermedius* in, 19:70–73
 Hepatitis, viral, 19:249
 Herpes simplex virus (HSV), transport media for viability maintenance of, 19:137–142
 HH medium, virus survival in, 19:137–142
 HIV. *See* Human immunodeficiency virus
 Hospital-acquired infections
 cefaclor against, 18:129
 cefprozil against, 18:129
 Enterobacteriaceae in, 20:203–208
 Pseudomonas stutzeri in, 19:51–56
 HPV. *See* Human papillomavirus
 HR 111V. *See* Cefquinome

HSV. *See* Herpes simplex virus

Human immunodeficiency virus (HIV)

- Actinobacillus ureae* meningitis in, 20:105–107
- Coccidioides immitis* in, 18:83–87
- Mycobacterium genavense* in, 18:7–12

Human papillomavirus (HPV) DNA, non-radioactive hybridization in detection of, 18:95–100

Hyaluronic acid capsules, on group A streptococci, 20:77–80

Hydrocephalus, *Candida* spp. in, 20:33–40

Hydrophobicity, roxithomycin effect on, 20:7–11

ICL series monoclonal antibodies, to *Shigella dysenteriae* serotype 13, 18:145–149

IFA. *See* Immunofluorescent assay

IgG

- Chlamydia pneumoniae* and, 18:229–233
- against *Clostridium difficile* toxins A and B, 18:205–209
- cytomegalovirus, 20:109–112
- Toxoplasma gondii*-specific, 19:19–24

IgM

- Chlamydia pneumoniae* and, 18:229–233
- cytomegalovirus, 20:109–112

Imipenem

- against *Acinetobacter* spp., 19:151–156
- against anaerobic bacteria, 19:129–133
- against *Bacteroides fragilis*, 18:193, 18:235–241, 19:129–133, 20:213–220
- cefepime and, 19:33–38
- against *Citrobacter freundii*, 19:151–156
- against *Clostridium perfringens*, 18:193
- against *Clostridium* spp., 20:213–220
- against *Enterobacter cloacae*, 19:151–156
- against *Enterobacter* spp., 18:251–258
- against *Enterococcus faecalis*, 19:151–156
- against *Escherichia coli*, 19:151–156
- against *Eubacterium lentum*, 18:193
- against *Fusobacterium necrophorum*, 18:194
- against *Fusobacterium nucleatum*, 18:194
- against *Fusobacterium* spp., 20:213–220
- against Gram-negative bacilli, 19:111–120, 20:175–179
- against Gram-positive cocci, 19:111–120
- against *Klebsiella* spp., 18:251–258, 19:151–156
- against *Lactobacillus* spp., 20:213–220
- against *Legionella pneumophila*, 20:159–162
- against *Mobiluncus* spp., 20:213–220
- against *Nocardia* spp., 19:101–110
- against *Peptostreptococcus anaerobius*, 18:193
- against *Peptostreptococcus* spp., 20:213–220
- against *Prevotella bivia/disiens*, 20:213–220
- against *Proteus* spp., 19:151–156
- against *Pseudomonas aeruginosa*, 18:251–258, 19:151–156
- against *Serratia marcescens*, 19:151–156
- against staphylococci, 20:175–179
- against *Staphylococcus aureus*, 19:151–156, 20:175–179
- against *Streptococcus pneumoniae*, 20:175–179

in US national surveillance study, 19:204–215

against *Veillonella parvula*, 18:194

Immediate-early gene, of cytomegalovirus DNA, 20:13–19

Immunocompromised host, *Oerskovia xanthineolytica* bacteremia in, 18:259–261

Immunofluorescent assay (IFA), for *Cryptosporidium* and *Giardia*, 19:89–91

Indirect immunofluorescence, for varicella-zoster virus, 20:117

Infectious diseases, understanding, 19:135

Inoculum density, effect of on minimum inhibitory concentrations, 18:191–195

Intestinal tract

- adenoviruses in, 18:161–166
- Candida* spp. in, 20:33–40
- Mycobacterium genavense* in, 18:7–12

Iron–hematoxylin staining, for *Cryptosporidium* and *Giardia*, 19:89–91

Isoniazid, against *Mycobacterium genavense*, 18:10

Itraconazole

- against *Candida* spp., 19:75–80
- against *Candida lusitaniae*, 20:127–133
- against *Sporothrix schenckii*, 18:111–115
- against *Torulopsis glabrata*, 19:75–80

Kanamycin

- against enterococci, 20:61–67
- against *Mycobacterium genavense*, 18:10

Karyotyping, of *Candida lusitaniae*, 20:127–133

Kill curves, Etest technology and, 19:187–195

Kinyon staining, for *Cryptosporidium* and *Giardia*, 19:89–91

Klebsiella oxytoca

- amoxicillin–clavulanate against, 18:184
- cefaclor against, 18:130, 18:184
- cefdinir against, 18:31–39
- cefepime against, 18:168
- cefixime against, 18:184
- cefprozil against, 18:130
- ceftazidime against, 18:168
- cefuroxime against, 18:184
- ciprofloxacin against, 18:184, 19:235–243
- CP-99,219 against, 19:235–243
- FK-037 against, 18:168
- fleroxacin against, 18:184
- lomefloxacin against, 18:184
- ofloxacin against, 18:184
- sparfloxacin against, 19:235–243
- trimethoprim–sulfamethoxazole against, 18:184

Klebsiella pneumoniae

- amoxicillin–clavulanate against, 18:184
- cefaclor against, 18:130, 18:184
- cefdinir against, 18:31–39
- cefixime against, 18:184
- cefprozil against, 18:130
- ceftazidime against, 20:203–208
- cefuroxime against, 18:184, 20:203–208
- ciprofloxacin against, 18:184, 19:235–243
- CP-99,219 against, 19:235–243
- fleroxacin against, 18:184
- gentamicin against, 20:203–208
- lomefloxacin against, 18:184

Leukocytes, stability of in refrigerated urine, 18:79–81

Levofloxacin

- against *Enterococcus faecalis*, 19:65–68

ofloxacin against, 18:184, 20:203–208

sparfloxacin against, 19:235–243

in spontaneous bacterial peritonitis, 19:3

Streptococcus pneumoniae and, 20:187–193

trimethoprim–sulfamethoxazole against, 18:184

in US national surveillance study, 19:204–215

Klebsiella spp.

- amikacin against, 19:151–156
- aztreonam against, 18:251–258
- Bauer–Kirby disk diffusion for, 18:251–258
- cefoperazone against, 18:251–258
- ceftazidime against, 18:251–258, 19:151–156
- ceftriaxone against, 18:251–258
- ciprofloxacin against, 18:251–258, 19:151–156
- FK-307 against, 20:27–32
- gentamicin against, 18:251–258, 19:151–156
- imipenem against, 18:251–258, 19:151–156
- piperacillin against, 18:251–258, 19:151–156
- piperacillin–tazobactam against, 19:151–156
- serial plate agar dilution for, 18:251–258
- ticarcillin–clavulanic acid against, 18:251–258, 19:151–156
- tobramycin against, 18:251–258

in US national surveillance study, 19:203–215

Vitek AutoMicrobic system for, 18:251–258

Kloos and Schleifer method, for staphylococci, 18:1–5, 18:151–155

Lactobacillus spp.

- ampicillin–sulbactam against, 20:213–220
- cefotaxime against, 20:213–220
- clindamycin against, 20:213–220
- imipenem against, 20:213–220

Lactoferrin, *Salmonella* spp. interaction with, 20:69–75

Larvae, *Strongyloides stercoralis*, 18:19–23

Latex agglutination assays

- for adenoviruses, 18:157–159
- for cytomegalovirus antibody, 20:109–112
- for *Salmonella typhi*, 18:75–78
- for *Staphylococcus aureus*, 19:5–8
- for *Streptococcus pneumoniae*, 18:211–214
- for varicella-zoster virus, 20:117

Legionella pneumophila

- cefdinir against, 18:31–39
- Etest for, 20:159–162
- imipenem against, 20:159–162
- sparfloxacin against, 20:159–162

Legionella spp.

- clindamycin against, 19:175–178
- doxycycline against, 19:175–178
- erythromycin against, 19:175–178
- ofloxacin against, 19:175–178
- rifampin against, 19:175–178

Leukocytes, stability of in refrigerated urine, 18:79–81

Levofloxacin

- against *Enterococcus faecalis*, 19:65–68

against *Escherichia coli*, 18:57-59
 against *Haemophilus influenzae*, 19:65-68
 against *Listeria monocytogenes*, 20:21-25
 against *Neisseria gonorrhoeae*, 19:65-68
 against *Pseudomonas aeruginosa*, 19:65-68
 against *Staphylococcus aureus*, 18:57-59, 19:65-68
 Lim broth, *Streptococcus* group B cultures and, 18:141-144
 Lincomycin, *mecA* gene and, 19:25-31
 Lipopolysaccharide antigen, of *Shigella dysenteriae* serotype 13, 18:145-149
Listeria monocytogenes
 ampicillin against, 20:21-25
 ciprofloxacin against, 20:21-25
 levofloxacin against, 20:21-25
 lomefloxacin against, 20:21-25
 ofloxacin against, 20:21-25
 sparfloxacin against, 20:21-25
 temofloxacin against, 20:21-25
 trimethoprim-sulfamethoxazole against, 20:21-25
 Lithium heparin, *Streptococcus pneumoniae* and, 20:187-193
 Lomefloxacin
 against *Citrobacter freundii*, 20:93-98
 against Gram-negative bacilli, 18:181-189
 against *Listeria monocytogenes*, 20:21-25
 against *Neisseria gonorrhoeae*, 20:93-98
 against *Neisseria meningitidis*, 20:93-98
 against *Providencia rettgeri*, 20:93-98
 against *Pseudomonas aeruginosa*, 20:93-98
 against *Salmonella enteriditis*, 20:93-98
 against *Shigella* spp., 20:93-98
 in US national surveillance study, 19:204-215
 LY121019. *see* Cilofungin
 M23-A guidelines, for DU-6859a and FK-307 susceptibility testing, 19:93-99
 M27-P macrodilution method
 for *Candida* spp., 18:89-94
 fluconazole and, 20:81-91
 for yeasts, 19:9-13, 19:217-220
 Macrobroth dilution method, for *Candida* spp., 18:89-94
 Macrolides
 against *Enterococcus faecium*, 20:41-43
 against *Haemophilus influenzae*, 18:243-249
 against *Mycoplasma hominis*, 20:57-59
 against *Mycoplasma pneumoniae*, 20:57-59
 against *Mycoplasma* spp., 20:57-59
 against *Ureaplasma urealyticum*, 20:57-59
 MBCs. *See* Minimum bactericidal concentrations
 McCoy cell culture, for chlamydial antigen, 18:101-104
 McFarland nephelometer, inoculum density and, 18:191-195
mec gene, in staphylococci, 19:167-170
mecA gene, in *Staphylococcus aureus*, 19:25-31
 Meningitis
Actinobacillus ureae in, 20:105-107
Streptococcus pneumoniae in, 18:211-214
 Meningoencephalitis
Candida spp. in, 20:33-40
Sporothrix spp. in, 18:111-115
 Mercia Toxo-G enzyme immunoassay, for *Toxoplasma*-specific IgG, 19:19-24
 Merifluor C/G stain, for *Cryptosporidium* spp., 19:221-225
 Merifluor immunofluorescent assay, for *Cryptosporidium* and *Giardia*, 19:89-91
 Methanol fixation, of *Pneumocystis carinii*-containing specimen, 18:197-199
 Methicillin, against staphylococci, 18:50-56, 18:121-124, 19:143-147, 19:167-170, 20:27-32, 20:171-174
 Metronidazole
 against anaerobic bacteria, 19:129-133
 against *Bacteroides capillosus*, 19:227-234
 against *Bacteroides fragilis*, 18:235-241, 19:129-133, 19:227-234, 20:135-142
 against *Clostridium* spp., 19:227-234, 20:135-142
 against *Eubacterium* spp., 19:227-234, 20:135-142
 against *Fusobacterium* spp., 19:227-234
 against *Peptostreptococcus* spp., 19:227-234, 20:135-142
 against *Porphyromonas* spp., 19:227-234
 against *Prevotella* spp., 19:227-234, 20:135-142
 against *Veillonella parvula*, 19:227-234, 20:135-142
 Mezlocillin
 against *Bacteroides fragilis*, 18:193
 against *Bacteroides thetaiotaomicron*, 18:193
 against *Clostridium perfringens*, 18:193
 against *Eubacterium lentum*, 18:193
 against *Fusobacterium necrophorum*, 18:194
 against *Fusobacterium nucleatum*, 18:194
 against *Veillonella parvula*, 18:194
 Microbial Identification System, for mycobacteria, 19:81-88
 Microbroth dilution
 of cefdinir, 18:31-39
 for *Nocardia* spp., 19:101-110
 Microimmunofluorescence (MIF) test, for *Chlamydia pneumoniae*, 18:229-233
 MicroScan Pos ID panel, for coagulase-negative staphylococci, 18:1-5
 MicroScan Rapid Pos ID panel, for coagulase-negative staphylococci, 18:1-5
 Microtrak II enzyme immunoassay, for *Chlamydia trachomatis*, 20:195-201
 MICs. *See* Minimum inhibitory concentrations
 MIF test. *See* Microimmunofluorescence test
 Minimum bactericidal concentrations (MBCs)
 chloramphenicol, 20:42
 Etest technology and, 19:187-195
 RP59,500, 20:42
 tetracycline, 20:42
 Minimum inhibitory concentrations (MICs)
 amikacin, 18:10, 19:101-110, 19:151-156, 19:183-186, 20:175-179
 aminoglycoside, 19:39-46, 20:41-43, 20:61-67
 amoxicillin-clavulanate, 18:25-30, 18:33, 18:183-188, 18:235-241, 19:227-234
 amoxicillin-clavulanic acid, 19:101-110
 amphotericin B, 18:89-94, 19:9-13, 19:75-80, 20:127-133
 ampicillin, 18:25-30, 18:105-109, 19:71, 19:171-173, 20:21-25, 20:41-43, 20:61-67, 20:69-75, 20:143-149, 20:151-158
 ampicillin-sulbactam, 18:235-241, 19:111-120, 19:227-234, 20:143-149, 20:213-220
 aztreonam, 18:251-258, 19:111-120
 bacitracin, 18:105-109
 β -lactam, 19:111-120
 biapenem, 19:65-68
 cefaclor, 18:33, 18:43, 18:129, 18:183-188
 cefalexin, 20:69-75
 cefdinir, 18:31, 18:43
 cefepime, 20:27-32, 20:49-55
 cefixime, 18:33, 18:183-188
 cefmetazole, 18:235-241
 cefoperazone, 18:193-194, 18:235-241, 18:251-258
 cefoperazone-sulbactam, 18:235-241
 cefotaxime, 18:61, 18:193-194, 18:235-241, 19:71, 19:101-110, 19:111-120, 20:49-55, 20:135-142, 20:143-149, 20:213-220
 cefotetan, 18:193-194, 18:235-241, 19:111-120
 cefoxitin, 18:25-30, 18:178, 18:193-194, 18:235-241, 19:111-120, 19:183-186, 20:135-142
 cefpirome, 20:27-32, 20:49-55
 cefpodoxime, 18:33
 cefpodoxime proxetil, 18:43
 cefprozil, 18:129
 cefquinome, 20:49-55
 ceftazidime, 18:251-258, 19:111-120, 19:151-156, 20:27-32, 20:49-55, 20:175-179, 20:203-208
 ceftazidime-netilmicin, 19:39-46
 ceftazidime-tobramycin, 19:39-46
 ceftizoxime, 18:193-194, 18:235-241, 19:65, 19:69, 20:135-142
 ceftriaxone, 18:178, 18:193-194, 18:235-241, 18:251-258, 19:101-110, 19:111-120, 19:227-234, 20:135-142, 20:143-149
 ceftriaxone-netilmicin, 19:39-46
 ceftriaxone-tazobactam, 19:227-234
 ceftriaxone-tobramycin, 19:39-46
 cefuroxime, 18:183-188, 19:111-120, 20:69-75, 20:143-149, 20:203-208
 cephalaxin, 18:33
 cephalosporin, 18:235-241, 20:27-32
 cephamin, 18:235-241
 chloramphenicol, 18:25-30, 19:71, 20:69-75, 20:151-158
 cilofungin, 18:89-94
 ciprofloxacin, 18:10, 18:51, 18:61, 18:183-188, 18:251-258, 19:71, 19:101-110, 19:111-120, 19:129-133, 19:143-147, 19:151-156, 19:171-173, 19:179-181, 19:183-186, 19:235-243, 20:27-32, 20:69-75, 20:167-170
 clarithromycin, 18:10
 clindamycin, 18:25-30, 18:235-241, 19:71, 19:129-133, 19:175-178, 20:213-220
 clofazimine, 18:10
 cotrimoxazole, 20:151-158
 CP-99,219, 19:235-243, 20:167-170

D0870, 19:75-80
 dirithromycin, 20:57-59
 doxycycline, 19:171-173, 19:175-178, 19:183-186, 20:41-43
 DU-6859a, 18:57-59, 18:125-127, 19:65-68, 19:93-99, 20:45-47
 enoxacin, 19:143-147
 erythromycin, 19:71, 19:171-173, 19:175-178, 20:57-59, 20:69-75
 ethambutol, 18:10
 FK-037, 19:65-68, 19:93-99, 20:175-179
 fleroxacin, 18:183-188, 19:129-133
 fluconazole, 19:9-13, 19:75-80, 19:217-220, 20:81-91, 20:127-133
 5-fluorocytosine, 18:89-94, 19:9-13, 19:75-80, 19:217-220, 20:127-133
 fluoroquinolone, 20:21-25, 20:45-47, 20:93-98
 gentamicin, 18:251-258, 19:57-60, 19:151-156, 19:171-173, 20:27-32, 20:61-67, 20:69-75, 20:203-208
 grepafloxacin, 19:65, 19:69, 19:129-133
 imipenem, 18:193-194, 18:235-241, 18:251-258, 19:101-110, 19:111-120, 19:129-133, 19:151-156, 20:27-32, 20:159-162, 20:175-179, 20:213-220
 inoculum effects on, 18:191-195, 19:163-166
 isoniazid, 18:10
 itraconazole, 19:75-80, 20:127-133
 kanamycin, 18:10, 20:61-67
 levofloxacin, 18:57-59, 19:65, 19:69, 20:21-25
 lomefloxacin, 18:183-188, 20:21-25, 20:93-98
 macrolide, 20:41-43, 20:57-59
 methicillin, 20:151-158
 metronidazole, 18:235-241, 19:129-133, 19:227-234, 20:135-142
 mezlocillin, 18:193-194
 minocycline, 19:101-110
 mupirocin, 20:171-174
 netilmicin, 19:39-46
 norfloxacin, 19:143-147
 ofloxacin, 18:10, 18:51, 18:57-59, 18:183-188, 19:143-147, 19:175-178, 20:21-25, 20:203-208
 oxacillin, 18:33, 18:43, 19:25-31, 19:167-170, 20:143-149
 penicillin, 18:178, 18:235-241, 20:151-158
 penicillin G, 19:71, 20:151-158
 penicillin V, 18:43
 piperacillin, 18:25-30, 18:251-258, 19:111-120, 19:151-156, 19:163-166, 20:135-142, 20:143-149
 piperacillin-tazobactam, 18:25-30, 18:235-241, 19:111-120, 19:151-156, 19:163-166, 19:227-234, 20:143-149
 polymyxin B, 20:69-75
 pyrazinamide, 18:10
 quinolone, 20:41-43
 rifabutin, 18:10
 rifampicin, 20:69-75
 rifampin, 18:10, 19:175-178, 19:179-181, 19:183-186
 Ro 23-9424, 18:61
 Ro 25-0534, 18:61
 roxithromycin, 20:7-11
 sparfloxacin, 18:10, 19:235-243, 20:21-25, 20:159-162
 spectinomycin, 18:178
 streptomycin, 18:10, 20:61-67
 tazobactam, 19:227-234
 temofloxacin, 20:21-25
 tetracycline, 18:178, 19:71, 20:57-59, 20:151-158
 ticarcillin, 18:25-30
 ticarcillin-clavulanate, 18:25-30, 19:111-120, 19:227-234
 ticarcillin-clavulanic acid, 18:251-258, 19:151-156, 20:143-149
 tobramycin, 18:251-258, 19:39-46
 trimethoprim, 19:71
 trimethoprim-sulfamethoxazole, 18:183-188, 19:101-110, 19:183-186, 20:21-25, 20:151-158
 vancomycin, 18:43, 18:105-109, 19:71, 19:171-173, 20:41-43, 20:61-67
 Minocycline, against *Nocardia* spp., 19:101-110
 Mitochondrial rRNA gene, of *Pneumocystis carinii*, 18:197-199
Mobiluncus mulieris, in extragenital infections, 20:163-165
Mobiluncus spp.
 ampicillin-sulbactam against, 20:213-220
 cefotaxime against, 20:213-220
 clindamycin against, 20:213-220
 imipenem against, 20:213-220
 Monoclonal antibodies
 lactoferrin interaction with *Salmonella* spp. and, 20:69-75
 to *Shigella dysenteriae* serotype 13, 18:145-149
Moraxella catarrhalis
 amoxicillin-clavulanate against, 18:186
 ampicillin against, 20:143-149
 ampicillin-sulbactam against, 20:143-149
 cefaclor against, 18:129-132, 18:186
 cefdinir against, 18:31-39
 cefepime against, 20:49-55
 cefixime against, 18:186
 cefotaxime against, 18:61-68, 20:49-55, 20:143-149
 cefpirome against, 20:49-55
 cefquinome against, 20:49-55
 ceftazidime against, 20:49-55
 ceftriaxone against, 20:143-149
 cefuroxime against, 18:186, 20:143-149
 ciprofloxacin against, 18:61-68, 18:186
 cefprozil against, 18:129-132
 DU-6859a against, 18:126
 fleroxacin against, 18:186
 lomefloxacin against, 18:186
 ofloxacin against, 18:186
 oxacillin against, 20:143-149
 piperacillin against, 20:143-149
 piperacillin-tazobactam against, 20:143-149
 Ro 23-9424 against, 18:61-68
 Ro 25-0534 against, 18:61-68
 trimethoprim-sulfamethoxazole against, 18:186
Morganella morganii
 amoxicillin-clavulanate against, 18:184
 cefaclor against, 18:184
 cefepime against, 18:168, 19:35
 cefixime against, 18:184
 ceftazidime against, 18:168
 cefuroxime against, 18:184
 ciprofloxacin against, 18:184, 19:235-243
 CP-99,219 against, 19:235-243
 FK-037 against, 18:168, 20:27-32
 fleroxacin against, 18:184
 lomefloxacin against, 18:184
 ofloxacin against, 18:184
 sparfloxacin against, 19:235-243
 trimethoprim-sulfamethoxazole against, 18:184
 Mouse infection models, *Staphylococcus aureus* and *Haemophilus influenzae* in, 18:41-47
 MRC-5 tissue cytotoxicity assay, serum-neutralizing assay based on, 18:205-209
 Mueller-Hinton medium
 for *Nocardia* spp., 19:101-110
 for staphylococci, 19:167-170
 Multilocus enzyme electrophoresis, of *Pseudomonas cepacia*, 20:181-186
 Multiplex-polymerase chain reaction assay, of oxacillin resistance in *Staphylococcus aureus*, 19:25-31
 Mupirocin, against *Staphylococcus aureus*, 20:171-174
 Mycobacteria
 acridinium-ester-labeled DNA probes for, 18:137-139
 computer-aided gas-liquid chromatography for, 19:81-88
Mycobacterium avium
 acridinium-ester-labeled DNA probes for, 18:137-139
Nocardia differentiated from, 18:15
 sulfamethoxazole against, 18:201-204
 sulfisoxazole against, 18:201-204
 trimethoprim against, 18:201-204
 trimethoprim-sulfamethoxazole against, 18:201-204
Mycobacterium avium-intracellulare complex
 ciprofloxacin against, 19:179-181
 rifampin against, 19:179-181
Mycobacterium fortuitum
 amikacin against, 19:183-186
 cefoxitin against, 19:183-186
 ciprofloxacin against, 19:183-186
 doxycycline against, 19:183-186
Nocardia differentiated from, 18:15
 rifampin against, 19:183-186
 trimethoprim-sulfamethoxazole against, 19:183-186
Mycobacterium genavense
 in AIDS, 18:7-12
 amikacin against, 18:10
 ciprofloxacin against, 18:10
 clarithromycin against, 18:10
 clofazimine against, 18:10
 ethambutol against, 18:10
 isoniazid against, 18:10
 kanamycin against, 18:10
 ofloxacin against, 18:10
 pyrazinamide against, 18:10
 rifabutin against, 18:10
 rifampin against, 18:10

sparfloxacin against, 18:10
streptomycin against, 18:10

Mycobacterium gordoneae, *Nocardia* differentiated from, 18:15

Mycobacterium intracellulare
Nocardia differentiated from, 18:15
sulfamethoxazole against, 18:201–204
sulfisoxazole against, 18:201–204
trimethoprim against, 18:201–204
trimethoprim-sulfamethoxazole, 18:201–204

Mycobacterium leprae, *Nocardia* differentiated from, 18:15

Mycobacterium scrofulaceum, *Nocardia* differentiated from, 18:15

Mycobacterium simiae, *Nocardia* differentiated from, 18:15

Mycobacterium spp., PCR-RFLP analysis of, 18:13–18

Mycobacterium szulgai, *Nocardia* differentiated from, 18:15

Mycobacterium tuberculosis
ciprofloxacin against, 19:179–181
Nocardia differentiated from, 18:15
rifampin against, 19:179–181
rifampin resistance locus and, 18:219–227
10-kD antigen structural gene in, 18:215–218

Mycobacterium xenopi, *Nocardia* differentiated from, 18:15

Mycoplasma hominis
dirithromycin against, 20:57–59
erythromycin against, 20:57–59
macrolides against, 20:57–59
tetracycline against, 20:57–59

Mycoplasma pneumoniae
dirithromycin against, 20:57–59
erythromycin against, 20:57–59
macrolides against, 20:57–59
tetracycline against, 20:57–59

Mycoplasma spp.
dirithromycin against, 20:57–59
erythromycin against, 20:57–59
macrolides against, 20:57–59
tetracycline against, 20:57–59

Nalidixic acid, *Streptococcus* group B cultures and, 18:141–144

NAP. *See p*-Nitro- α -acetylaminob- β -hydroxypropiophenone

Nasal isolates, of *Staphylococcus aureus*, 20:171–174

National Committee for Clinical Laboratory Standards (NCCLS)
disk diffusion susceptibility testing criteria of, 18:175
Haemophilus test medium and, 18:243–249
M23-A guidelines of, 19:93–99
M27-P macrodilution method of, 19:9–13, 19:217–220, 20:81–91
macrobroth dilution test of, 18:89–94
microdilution broth method of, 19:75–80
minimum inhibitory concentration quality-control guidelines of, 19:65–68

NCCLS. *See* National Committee for Clinical Laboratory Standards

Neisseria gonorrhoeae
amoxicillin-probenecid against, 19:121–127

ampicillin against, 19:121–127
cefdinir against, 18:31–39
cefepime against, 20:49–55
cefotaxime against, 20:49–55
cefoxitin against, 18:177–178
cefprome against, 20:49–55
cefquinome against, 20:49–55
ceftamet pivoxil against, 19:121–127
ceftazidime against, 20:49–55
ceftizoxime against, 19:65–68
ceftriaxone against, 18:175, 18:177–178
cephalosporins against, 19:121–127
FK-037 against, 19:65–68
grepafloxacin against, 19:65–68
levofloxacin against, 19:65–68
lomefloxacin against, 20:93–98
penicillin against, 18:177–178
spectinomycin against, 18:177–178, 19:121–127
susceptibility tests for, 18:175
tetracycline against, 18:175, 18:177–178
thiamphenicol against, 19:121–127

Neisseria meningitidis
lomefloxacin against, 20:93–98
Streptococcus pneumoniae and, 20:187–193

Neonatal care unit, adenoviruses in, 18:157–159

Netilmicin, against *Pseudomonas aeruginosa*, 19:39–46

p-Nitro- α -acetylaminob- β -hydroxypropiophenone (NAP), in inhibition of *Mycobacterium genavense*, 18:7–12

Nitrocefin test, for enterococci, 20:61–67

Nocardia asteroides, *Mycobacterium* spp. differentiated from, 18:13–18

Nocardia spp.
amikacin against, 19:101–110
amoxicillin-clavulanic acid against, 19:101–110
cefotaxime against, 19:101–110
ceftriaxone against, 19:101–110
ciprofloxacin against, 19:101–110
Etest for, 19:101–110
imipenem against, 19:101–110
minocycline against, 19:101–110
Oerskovia xanthineolytica and, 18:259–261
PCR-RFLP analysis of, 18:13–18
trimethoprim-sulfamethoxazole against, 19:101–110

Nonradioactive hybridization, for human papillomavirus, 18:95–100

Nonradioactive probe, for cytomegalovirus, 20:13–19

Nonradiometric culture system, for spontaneous bacterial peritonitis, 19:1–4

Norfloxacin
against staphylococci, 19:143–147
against *Staphylococcus aureus*, 19:143–147
against urinary tract isolates, 18:49–56
in US national surveillance study, 19:204–215

Nosocomial infections
Candida lusitaniae in, 20:127–133
Enterococcus faecalis in, 19:197–202
Enterococcus faecium in, 18:105–109, 20:41–43

Nucleotide sequence homology, between mycobacteria and nocardiae, 18:13–18

Oerskovia xanthineolytica bacteremia, in immunocompromised patient with pneumonia, 18:259–261

Ofloxacin
against *Acinetobacter* spp., 18:50–56
ciprofloxacin and, 18:49–56
against *Enterococcus faecium*, 20:42
against *Enterococcus* spp., 18:50–56
against *Escherichia coli*, 18:57–59, 20:203–208
against Gram-negative bacilli, 18:181–189
against Gram-positive cocci, 18:50–56
against *Klebsiella pneumoniae*, 20:203–208
against *Legionella* spp., 19:175–178
against *Listeria monocytogenes*, 20:21–25
against *Mycobacterium genavense*, 18:10
against staphylococci, 18:50–56, 19:143–147
against *Staphylococcus aureus*, 18:57–59, 19:143–147
in US national surveillance study, 19:203–215

OPC-17116. *See* Grepafloxacin

Oral contraceptive use, human papillomavirus risk and, 18:95–100

Ornithosis antigen, *Chlamydia pneumoniae* and, 18:229–233

Oxacillin, against staphylococci, 18:31–39, 18:43, 18:61, 18:121–124, 18:125, 18:167–173, 18:181–189, 19:25–31, 19:167–170, 19:204–215, 20:143–149

PAEs. *See* Postantibiotic effects

Pasco Gram-negative nonfermenter identification system, evaluation of, 19:61–63

Pasteurella ureae
ceftriaxone against, 20:105–107
penicillin against, 20:105–107

PCR. *See* Polymerase chain reaction

PCR-RFLP analysis, of *Mycobacterium* and *Nocardia*, 18:13–18

Pefloxacin, *mecA* gene and, 19:25–31

Penicillin
against *Bacteroides fragilis*, 18:235–241
against *Aspergillus ureae*, 20:105–107
against enterococci, 19:57–60
against *Neisseria gonorrhoeae*, 18:177–178
against *Pasteurella ureae*, 20:105–107
against pneumococci, 18:61, 19:157–161
against *Pseudomonas stutzeri*, 19:51–56
against *Streptococcus pneumoniae*, 18:31–39, 19:157–161
in US national surveillance study, 19:204–215

Penicillin-aminoglycosides, against enterococci, 19:57–60

Penicillinase, in oxacillin resistance in *Staphylococcus aureus*, 19:25–31

Penicillin G, against *Streptococcus milleri* group, 19:70–73

Penicillin V, against *Staphylococcus aureus*, 18:43

Peptostreptococcus spp.
amoxicillin-clavulanate against, 19:227–234
ampicillin-sulbactam against, 19:227–234, 20:213–220

cefotaxime against, 20:213–220, 20:135–142
 cefoxitin against, 20:135–142
 ceftizoxime against, 20:135–142
 ceftriaxone against, 19:227–234, 20:135–142
 ceftriaxone–tazobactam against, 19:227–234
 clindamycin against, 20:213–220
 imipenem against, 20:213–220
 metronidazole against, 19:227–234, 20:135–142
 piperacillin against, 20:135–142
 piperacillin–tazobactam against, 19:227–234
 tazobactam against, 19:227–234
 ticarcillin–clavulanate against, 19:227–234
 Percoll, hyaluronic acid capsules on group A streptococci and, 20:77–80
 Peripheral blood leukocytes
 cytomegalovirus in, 20:13–19
 pp65 antigen in, 19:15–18
 Peritonitis
Aspergillus, 20:99–103
 Etest and, 20:213–220
 spontaneous bacterial, 19:1–4
 Peroxidase, lactoferrin interaction with *Salmonella* spp. and, 20:69–75
 PFGE. *See* Pulsed-field gel electrophoresis
 pH
 leukocyte stability in refrigerated urine and, 18:79–81
Mycobacterium genavense and, 18:7–12
 Piperacillin
 against *Acinetobacter* spp., 19:151–156
 against *Bacteroides fragilis*, 20:135–142
 against *Citrobacter freundii*, 19:151–156
 against *Enterobacter cloacae*, 19:151–156
 against *Enterobacteriaceae*, 20:143–149
 against *Enterobacter* spp., 18:251–258
 against *Enterococcus faecalis*, 19:151–156
 against *Enterococcus faecium*, 20:42
 against *Enterococcus* spp., 20:143–149
 against *Escherichia coli*, 19:151–156
 against Gram-negative bacilli, 18:25–30, 19:111–120
 against Gram-positive cocci, 19:111–120
 against *Haemophilus influenzae*, 20:143–149
 against *Klebsiella* spp., 18:251–258, 19:151–156
 against *Moraxella catarrhalis*, 20:143–149
 against *Prevotella* spp., 20:135–142
 against *Proteus* spp., 19:151–156
 against *Pseudomonas aeruginosa*, 18:251–258, 19:151–156, 20:143–149
 against *Serratia marcescens*, 19:151–156
 against *Staphylococcus aureus*, 19:151–156, 19:163–166
 against *Veillonella parvula*, 19:227–234
 PMNL, roxithromycin effect on, 20:7–11
 Pneumococci
 cefotaxime against, 18:61
 ciprofloxacin against, 18:61
 in Lebanese antimicrobial susceptibility study, 20:151–158
 in meningitis, 18:211–214
 penicillin against, 19:157–161
 Ro 23-9424 against, 18:61
 Ro 25-0534 against, 18:61
Pneumocystis carinii, DNA amplification of, 18:197–199
 Pneumonia, *Oerskovia xanthineolytica* bacteremia with, 18:259–261
 Polyclonal rabbit antiserum, for *Shigella dysenteriae* serotype 13, 18:145–149
 Polymerase chain reaction (PCR)
 of *Chlamydia trachomatis*, 20:195–201
 of cytomegalovirus, 20:13–19
 of *Mycobacterium* spp., 18:13–18
 of *Nocardia* spp., 18:13–18
 of *Pneumocystis carinii*, 18:197–199
 of rifampin resistance locus, 18:219–227
 of *Staphylococcus aureus*, 19:25–31
 of *Streptococcus pneumoniae*, 20:187–193
 of 10-kD antigen structural gene in *Mycobacterium tuberculosis*, 18:215–218
 Polymyxin B
 lactoferrin interaction with *Salmonella* spp. and, 20:69–75
 for *Mycobacterium chelonae* and *Mycobacterium fortuitum*, 19:183–186
 Porins, lactoferrin interaction with *Salmonella* spp. and, 20:69–75
Porphyromonas spp.
 amoxicillin–clavulanate against, 18:25–30, 19:227–234
 ampicillin against, 18:25–30
 ampicillin–sulbactam against, 19:227–234
 cefoxitin against, 18:25–30
 ceftriaxone against, 19:227–234
 ceftriaxone–tazobactam against, 19:227–234
 chloramphenicol against, 18:25–30
 clindamycin against, 18:25–30
 metronidazole against, 19:227–234, 20:135–142
 piperacillin against, 18:25–30, 20:135–142
 piperacillin–tazobactam against, 18:25–30, 19:227–234
 tazobactam against, 19:227–234
 ticarcillin against, 18:25–30
 ticarcillin–clavulanate against, 18:25–30, 19:227–234
 Postantibiotic effects (PAEs)
 of DU-6859a, 18:57–59
 Etest technology and, 19:187–195
 of levofloxacin, 18:57–59
 of roxithromycin, 20:7–11
 pp65 antigen, detection of, 19:15–18
 Pregnancy, human papillomavirus risk and, 18:95–100
Prevotella bivia/disiens
 ampicillin–sulbactam against, 20:213–220
 cefotaxime against, 20:213–220
 clindamycin against, 20:213–220
 imipenem against, 20:213–220
Prevotella spp.
 amoxicillin–clavulanate against, 18:25–30, 19:227–234
 ampicillin against, 18:25–30
 ampicillin–sulbactam against, 19:227–234
 cefotaxime against, 20:135–142
 cefoxitin against, 18:25–30, 20:135–142
 ceftizoxime against, 20:135–142
 ceftriaxone against, 19:227–234, 20:135–142
 ceftriaxone–tazobactam against, 19:227–234
 chloramphenicol against, 18:25–30
 clindamycin against, 18:25–30
 metronidazole against, 19:227–234, 20:135–142
 piperacillin against, 18:25–30, 20:135–142
 piperacillin–tazobactam against, 18:25–30, 19:227–234
 tazobactam against, 19:227–234
 ticarcillin against, 18:25–30
 ticarcillin–clavulanate against, 18:25–30, 19:227–234
 ProSpecT enzyme-linked immunosorbent assay, for *Cryptosporidium* spp., 19:221–225
 Proteinase K digestion, of *Pneumocystis carinii*-containing specimen, 18:197–199
Proteus mirabilis
 amoxicillin–clavulanate against, 18:184
 cefaclor against, 18:130, 18:184
 cefdinir against, 18:31–39
 cefepime against, 18:168
 cefixime against, 18:184
 cefprozil against, 18:130
 ceftazidime against, 18:168
 cefuroxime against, 18:184
 ciprofloxacin against, 18:184
 FK-037 against, 18:168, 20:27–32
 fleroxacin against, 18:184
 lomefloxacin against, 18:184
 ofloxacin against, 18:184
 trimethoprim–sulfamethoxazole against, 18:184
Proteus spp.
 amikacin against, 19:151–156
 ceftazidime against, 19:151–156

ciprofloxacin against, 19:151–156
 gentamicin against, 19:151–156
 imipenem against, 19:151–156
 piperacillin against, 19:151–156
 piperacillin–tazobactam against, 19:151–156
 ticarcillin–clavulanic acid against, 19:151–156
Proteus vulgaris
 cefepime against, 18:168
 ceftazidime against, 18:168
 FK-037 against, 18:168, 20:27–32
Providencia rettgeri
 cefepime against, 18:168, 18:207
 ceftazidime against, 18:168, 18:207
 FK-037 against, 18:168, 18:207
 lomefloxacin against, 20:93–98
Providencia spp.
 cefepime against, 18:167–173
 ceftazidime against, 18:167–173
 FK-037 against, 18:167–173
Providencia stuartii
 amoxicillin–clavulanate against, 18:184
 cefaclor against, 18:184
 cefepime against, 20:49–55
 cefixime against, 18:184
 cefotaxime against, 20:49–55
 cefpirome against, 20:49–55
 cefquinome against, 20:49–55
 ceftazidime against, 20:49–55
 cefuroxime against, 18:184
 ciprofloxacin against, 18:184
 FK-307 against, 20:27–32
 fleroxacin against, 18:184
 fluoroquinolones against, 18:181
 lomefloxacin against, 18:184
 ofloxacin against, 18:184
 trimethoprim–sulfamethoxazole against, 18:184
Pseudoepidemic, adenovirus, 18:157–159
Pseudomonas aeruginosa
 amikacin against, 19:151–156
 aminoglycosides against, 18:133–134
 amoxicillin–clavulanate against, 18:185
 ampicillin against, 20:143–149
 ampicillin–sulbactam against, 20:143–149
 aztreonam against, 18:251–258
 Bauer–Kirby disk diffusion for, 18:251–258
 biapenem against, 19:65–68
 cefaclor against, 18:185
 cefepime against, 18:167–173, 19:33–38, 20:49–55
 cefixime against, 18:185
 cefoperazone against, 18:251–258
 cefotaxime against, 18:61–68, 20:49–55, 20:143–149
 cefpirome against, 20:49–55
 cefquinome against, 20:49–55
 ceftazidime against, 18:167–173, 18:251–258, 19:151–156, 20:49–55
 ceftriaxone against, 18:251–258, 20:143–149
 ceftriaxone–aminoglycoside synergy against, 19:39–46
 cefuroxime against, 18:185, 20:143–149
 ciprofloxacin against, 18:61–68, 18:185, 18:251–258, 19:151–156, 19:235–243
 CP-99,219 against, 19:235–243
 DU-6859a against, 19:65–68
 FK-037 against, 18:167–173, 19:65–68
 fleroxacin against, 18:185
 gentamicin against, 18:134, 18:251–258, 19:151–156
 grepafloxacin against, 19:65–68
 imipenem against, 18:251–258, 19:151–156
 levofloxacin against, 19:65–68
 lomefloxacin against, 18:185, 20:93–98
 ofloxacin against, 18:185
 oxacillin against, 20:143–149
 Pasco Gram-negative nonfermenter system for, 19:61–63
 piperacillin against, 18:251–258, 19:151–156, 20:143–149
 piperacillin–tazobactam against, 19:151–156, 20:143–149
 Ro 23-9424 against, 18:61–68
 Ro 25-0534 against, 18:61–68
 serial plate agar dilution for, 18:251–258
 sparfloxacin against, 19:235–243
 ticarcillin–clavulanic acid against, 18:251–258, 19:151–156
 tobramycin against, 18:251–258
 trimethoprim–sulfamethoxazole against, 18:185
 in US national surveillance study, 19:203–215
 Vitek AutoMicrobic system for, 18:251–258
Pseudomonas cepacia, extended ribotyping of, 20:181–186
Pseudomonas spp.
 cefepime against, 18:167–173, 19:33–38
 ceftazidime against, 18:167–173
 ceftazidime against, 18:170
 DU-6859a against, 18:125
 FK-037 against, 18:167–173, 20:27–32
 fluoroquinolones against, 18:181
 in Lebanese antimicrobial susceptibility study, 20:151–158
Streptococcus pneumoniae and, 20:187–193
Pseudomonas stutzeri
 aminoglycosides against, 19:51–56
 cephalosporins against, 19:51–56
 penicillin against, 19:51–56
 trimethoprim–sulfamethoxazole against, 19:51–56
PstI, in ribotyping *Pseudomonas cepacia*, 20:181–186
 Pulmonary coccidioidomycosis, bronchoscopic diagnosis of, 18:83–87
 Pulmonary infection, *Oerskovia xanthineolytica* in, 18:259–261
 Pulsed-field gel electrophoresis (PFGE)
 of *Candida lusitaniae*, 20:127–133
 of *Enterococcus faecalis*, 19:197–202
 of extended-spectrum β -lactamases, 20:203–208
 Pyrazinamide, against *Mycobacterium genavense*, 18:10
 Pyrvinium pamoate, against *Strongyloides stercoralis*, 18:19–23
 Quinolones
 in disk diffusion tests, 18:125–127
 against *Enterococcus faecium*, 20:41–43
 against *Listeria monocytogenes*, 20:21–25
 Ramoplanin, bioassay for, 18:117–119
 Respiratory tract isolates
 cefdinir against, 18:31–39
 ciprofloxacin against, 18:49–56
 of *Enterococcus faecalis*, 19:197–202
 ofloxacin against, 18:49–56
 of *Pseudomonas stutzeri*, 19:51–56
 of *Streptococcus pneumoniae*, 19:157–161
 Respiratory syncytial virus (RSV), transport media for viability maintenance of, 19:137–142
 Restriction endonuclease analysis
 of adenoviruses, 18:161–166
 of *Candida lusitaniae*, 20:127–133
 of *Enterococcus faecalis*, 19:197–202
 of *Mycobacterium* spp., 18:13–18
 of *Nocardia* spp., 18:13–18
 Restriction fragment-length polymorphism (RFLP)
 in *Escherichia coli*, 18:263–265
 in *Mycobacterium* spp., 18:13–18
 in *Nocardia* spp., 18:13–18
 RFLP. *See* Restriction fragment-length polymorphism
 Rhesus monkey kidney cells, adenoviruses grown in, 18:161–166
 Ribotyping
 of *Escherichia coli*, 18:263–265
 of *Pseudomonas cepacia*, 20:181–186
 Richards viral transport medium, virus survival in, 19:137–142
 Rifabutin, against *Mycobacterium genavense*, 18:10
 Rifampicin, lactoferrin interaction with *Salmonella* spp. and, 20:69–75
 Rifampin
 against *Enterococcus faecium*, 20:42
 against *Legionella* spp., 19:175–178
 against *Mycobacterium cheloneae*, 19:183–186
 against *Mycobacterium fortuitum*, 19:183–186
 against *Mycobacterium genavense*, 18:10
 against *Mycobacterium tuberculosis*, 19:179–181
 resistance locus for, 18:219–227
 Ro 23-9424
 against *Acinetobacter* spp., 18:61–68
 against *Bacteroides fragilis*, 18:61–68
 against *Enterobacteriaceae*, 18:61
 against enterococci, 18:61
 against Gram-negative bacilli, 18:61
 against *Haemophilus influenzae*, 18:61–68
 against *Moraxella catarrhalis*, 18:61–68
 against pneumococci, 18:61
 against *Pseudomonas aeruginosa*, 18:61–68
 against staphylococci, 18:61
 against streptococci, 18:61
 against *Xanthomonas maltophilia*, 18:61–68
 Ro 25-0534
 against *Acinetobacter* spp., 18:61–68
 against *Bacteroides fragilis*, 18:61–68
 against *Enterobacteriaceae*, 18:61
 against enterococci, 18:61
 against Gram-negative bacilli, 18:61
 against *Haemophilus influenzae*, 18:61–68
 against *Moraxella catarrhalis*, 18:61–68
 against pneumococci, 18:61

against *Pseudomonas aeruginosa*, 18:61–68
 against staphylococci, 18:61
 against streptococci, 18:61
 against *Xanthomonas maltophilia*, 18:61–68
Roxithromycin, against *Streptococcus pyogenes*, 20:7–11
 RP59,500, against *Enterococcus faecium*, 20:42
RPMI-1640 medium
Candida spp. in, 18:89–94
 fluconazole and, 20:87–91
rpoB resistance locus, for rifampin, 18:219–227
RSV. *See* Respiratory syncytial virus

Saccharomyces cerevisiae
 amphotericin B against, 19:10
 fluconazole against, 19:10
 5-fluorocytosine against, 19:10
Salmonella enteriditis, lomefloxacin against, 20:93–98
Salmonella gloucester, multiple-drug-resistant, 20:209–211
Salmonella spp.
 cefepime against, 18:168
 ceftazidime against, 18:168
 ciprofloxacin against, 20:46
 DU-6859a against, 20:46
 FK-037 against, 18:168
 in Lebanese antimicrobial susceptibility study, 20:151–158
Salmonella typhi
 ciprofloxacin against, 20:46
 DU-6859a against, 20:46
 FK-307 against, 20:27–32
 in Lebanese antimicrobial susceptibility study, 20:151–158
 Vi-specific latex agglutination for, 18:75–78
 Selective sheep blood agar, *Streptococcus*, group B cultured on, 18:141–144
 Serial plate agar dilution
 for *Enterobacter* spp., 18:251–258
 for *Klebsiella* spp., 18:251–258
 for *Pseudomonas aeruginosa*, 18:251–258
 Serotype antigens, for *Streptococcus pneumoniae*, 18:211–214
Serratia liquefaciens
 cefepime against, 18:167–173
 ceftazidime against, 18:167–173
 FK-037 against, 18:167–173
Serratia marcescens
 amikacin against, 19:151–156
 amoxicillin-clavulanate against, 18:185
 cefaclor against, 18:130, 18:185
 cefepime against, 18:169
 cefixime against, 18:185
 cefprozil against, 18:130
 ceftazidime against, 18:169, 19:151–156
 cefuroxime against, 18:185
 ciprofloxacin against, 18:185, 19:151–156, 19:235–243
 CP-99,219 against, 19:235–243
 FK-037 against, 18:169, 20:27–32
 fleroxacin against, 18:185
 gentamicin against, 19:151–156
 imipenem against, 19:151–156
 lomefloxacin against, 18:185
 ofloxacin against, 18:185
Sparfloxacin
 against *Bacteroides fragilis*, 19:235–243
 against *Citrobacter diversus*, 19:235–243
 against *Citrobacter freundii*, 19:235–243
 against *Enterobacter aerogenes*, 19:235–243
 against *Enterobacter cloacae*, 19:235–243
 against *Enterobacteriaceae*, 19:235–243
 against *Enterococcus faecalis*, 19:235–243
 against *Enterococcus faecium*, 20:42
 against *Escherichia coli*, 19:235–243
 against *Helicobacter pylori*, 19:235–243
 against *Klebsiella oxytoca*, 19:235–243
 against *Klebsiella pneumoniae*, 19:235–243
 against *Legionella pneumophila*, 20:159–162
 against *Listeria monocytogenes*, 20:21–25
 against *Morganella morganii*, 19:235–243
 against *Mycobacterium genavense*, 18:10
 against *Pseudomonas aeruginosa*, 19:235–243
 against *Serratia marcescens*, 19:235–243
 against staphylococci, 19:235–243
 against *Streptococcus pneumoniae*, 19:235–243
 against *Streptococcus pyogenes*, 19:235–243
 Spearman rank correlation coefficient, for *Pseudomonas aeruginosa*, 19:39–46
 Spectinomycin, against *Neisseria gonorrhoeae*, 18:177–178, 19:121–127
 Spontaneous bacterial peritonitis, detection of, 19:1–4
Sporothrix schenckii
 amphotericin against, 18:111–115
 itraconazole against, 18:111–115
 Sputum, *Enterococcus faecalis* in, 19:197–202
SstII, 10-kD antigen structural gene in *Mycobacterium tuberculosis* and, 18:215–218
 Staphaurex, in identification of *Staphylococcus aureus*, 19:5–8
 Staphylococci
 cefotaxime against, 18:61
 ciprofloxacin against, 18:50–56, 19:143–147, 19:235–243
 CP-99,219 against, 19:235–243
 DU-6859a against, 18:125
 enoxacin against, 19:143–147
 fluoroquinolone-methicillin-resistant, 19:143–147
 norfloxacin against, 19:143–147
 ofloxacin against, 18:50–56, 19:143–147
 Ro 23-9424 against, 18:61
 Ro 25-0534 against, 18:61
 sparfloxacin against, 19:235–243
 Staphylococci, coagulase-negative
 amikacin against, 20:175–179
 cefepime against, 18:171, 18:209
 ceftazidime against, 18:171, 18:209, 20:175–179
 FK-037 against, 18:171, 18:209, 20:175–179
 fluoroquinolones against, 19:143–147
 identification systems for, 18:151–155
 imipenem against, 20:175–179
 in Lebanese antimicrobial susceptibility study, 20:151–158
 MicroScan Pos ID panel for, 18:1–5
 MicroScan Rapid Pos ID panel for, 18:1–5
 in spontaneous bacterial peritonitis, 19:3
Streptococcus pneumoniae and, 20:187–193

Staphylococcus aureus
 Accuprobe for, 19:5-8
 amikacin against, 19:151-156, 20:175-179
 amoxicillin-clavulanate against, 18:186
 ampicillin against, 18:41-47
 biapenem against, 19:65-68
 cefaclor against, 18:41-47, 18:130, 18:186
 cefdinir against, 18:31-47
 cefepime against, 18:167-173, 20:49-55
 cefixime against, 18:186
 cefotaxime against, 20:49-55
 cefpirome against, 20:49-55
 cefpodoxime proxetil against, 18:41-47
 cefprozil against, 18:130
 cefquinome against, 20:49-55
 ceftazidime against, 18:167-173, 19:151-156, 20:49-55, 20:175-179
 cefuroxime against, 18:186
 ciprofloxacin against, 18:186, 19:143-147, 19:151-156
 DU-6859a against, 18:57-59, 19:65-68
 enoxacin against, 19:143-147
 FK-037 against, 18:167-173, 19:65-68, 20:49-55, 20:175-179
 fleroxacin against, 18:186
 gentamicin against, 19:151-156
 grepafloxacin against, 19:65-68
 heat-stable thermonuclease for, 19:5-8
 imipenem against, 19:151-156, 20:175-179
 in Lebanese antimicrobial susceptibility study, 20:151-158
 levofloxacin against, 18:57-59, 19:65-68
 lomefloxacin against, 18:186
 mupirocin against, 20:171-174
 norfloxacin against, 19:143-147
 ofloxacin against, 18:57-59, 18:186, 19:143-147
 oxacillin against, 19:25-31, 19:167-170
 piperacillin against, 19:151-156, 163-166
 piperacillin-tazobactam against, 19:151-156, 19:163-166
 spontaneous bacterial peritonitis and, 19:3
Staphaurex for, 19:5-8
Streptococcus pneumoniae and, 20:187-193
 ticarcillin-clavulanic acid against, 19:151-156
 in toxic shock syndrome, 19:245-247
 trimethoprim-sulfamethoxazole against, 18:186
 in US national surveillance study, 19:203-215
Staphylococcus auricularis
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
Staphylococcus capitis
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
Staphylococcus cohnii
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
Staphylococcus epidermidis
 amoxicillin-clavulanate against, 18:187
 cefaclor against, 18:130, 18:187
 cefdinir against, 18:31-39
 cefepime against, 18:171
 cefixime against, 18:187
 cefprozil against, 18:130
 ceftazidime against, 18:171

cefuroxime against, 18:187
 ciprofloxacin against, 18:187
 FK-037 against, 18:171
 fleroxacin against, 18:187
 identification systems for, 18:151-155
 lomefloxacin against, 18:187
 MicroScan panels for, 18:1-5
 ofloxacin against, 18:187
 oxacillin against, 19:167-170
 trimethoprim-sulfamethoxazole against, 18:187
Staphylococcus haemolyticus
 cefaclor against, 18:130
 cefepime against, 18:171
 cefprozil against, 18:130
 ceftazidime against, 18:171
 FK-037 against, 18:171
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
 oxacillin against, 19:167-170
Staphylococcus hominis
 cefaclor against, 18:130
 cefepime against, 18:171
 cefprozil against, 18:130
 ceftazidime against, 18:171
 FK-037 against, 18:171
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
Staphylococcus intermedius, MicroScan panels for, 18:1-5
Staphylococcus lugdunensis, MicroScan panels for, 18:1-5
Staphylococcus saprophyticus
 cefaclor against, 18:130
 cefdinir against, 18:31-39
 cefepime against, 18:171
 cefprozil against, 18:130
 ceftazidime against, 18:171
 FK-037 against, 18:171
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
Staphylococcus schleiferi, MicroScan panels for, 18:1-5
Staphylococcus sciuri, MicroScan panels for, 18:1-5
Staphylococcus simulans
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
 oxacillin against, 19:167-170
Staphylococcus spp., optimizing testing of methicillin-resistant, 19:167-170
Staphylococcus warneri
 identification systems for, 18:152-153
 MicroScan panels for, 18:1-5
Staphylococcus xylosus, MicroScan panels for, 18:1-5
 STO antigens, for *Salmonella typhi*, 18:75-78
 Stool specimens
 adenoviruses in, 18:157-166
Cryptosporidium spp. in, 19:89-91, 19:221-225
Enterococcus faecium in, 18:105-109
Giardia spp. in, 19:89-91
Strongyloides stercoralis in, 18:19-23
Streptococci
 cefepime against, 18:167-173
 ceftazidime against, 18:167-173
 FK-037 against, 18:167-173

Streptococci, β -hemolytic
 cefepime against, 18:172
 cefotaxime against, 18:61
 ceftazidime against, 18:172
 ciprofloxacin against, 18:61
 FK-037 against, 18:167-173
 Ro 23-9424 against, 18:61
 Ro 25-0534 against, 18:61
Streptococci, group A
 cefaclor against, 18:130
 cefdinir against, 18:31-39
 cefprozil against, 18:130
 hyaluronic acid capsules on, 20:77-80
Streptococci, group B
 amoxicillin-clavulanate against, 18:187
 cefaclor against, 18:130, 18:187
 cefdinir against, 18:31-39
 cefixime against, 18:187
 cefprozil against, 18:130
 cefuroxime against, 18:187
 ciprofloxacin against, 18:187
 detection of, 18:141-144
 fleroxacin against, 18:187
 lomefloxacin against, 18:187
 ofloxacin against, 18:187
 trimethoprim-sulfamethoxazole against, 18:187
Streptococci, group C
 cefaclor against, 18:130
 cefprozil against, 18:130
Streptococci, group G
 cefaclor against, 18:130
 cefprozil against, 18:130
Streptococci, viridans group
 cefepime against, 18:172
 ceftazidime against, 18:172
 FK-037 against, 18:167-173
 spontaneous bacterial peritonitis and, 19:1-4
Streptococcus anginosus group, susceptibility patterns of, 19:70-73
Streptococcus imitis
 cefaclor against, 18:130
 cefprozil against, 18:130
Streptococcus intermedius group, susceptibility patterns of, 19:70-73
Streptococcus milleri group
 β -lactams against, 19:70-73
 chloramphenicol against, 19:70-73
 clindamycin against, 19:70-73
 erythromycin against, 19:70-73
 penicillin G against, 19:70-73
 tetracycline against, 19:70-73
 trimethoprim against, 19:70-73
 vancomycin against, 19:70-73
Streptococcus pneumoniae
 amikacin against, 20:175-179
 amoxicillin-clavulanate against, 18:187
 cefaclor against, 18:130, 18:187
 cefdinir against, 18:31-39
 cefixime against, 18:187
 cefprozil against, 18:130
 ceftazidime against, 20:175-179
 cefuroxime against, 18:187
 ciprofloxacin against, 18:187, 19:235-243
 CP-99,219 against, 19:235-243
 FK-037 against, 20:175-179
 fleroxacin against, 18:187

imipenem against, 20:175-179
 lomefloxacin against, 18:187
 in meningitis, 18:211-214
 ofloxacin against, 18:187
 penicillin against, 19:157-161
 polymerase chain reaction of, 20:187-193
 sparfloxacin against, 19:235-243
 trimethoprim-sulfamethoxazole against, 18:187
 in US national surveillance study, 19: 204-215

Streptococcus pyogenes
 ciprofloxacin against, 19:235-243
 CP-99,219 against, 19:235-243
 roxithromycin against, 20:7-11
 sparfloxacin against, 19:235-243
Streptococcus pneumoniae and, 20:187-193
 in toxic shock syndrome, 19:245-247

Streptococcus sanguis
 cefaclor against, 18:130
 cefprozil against, 18:130

Streptococcus spp.
 cefepime against, 18:172, 20:49-55
 cefotaxime against, 20:49-55
 cefpirome against, 20:49-55
 cefquinome against, 20:49-55
 ceftazidime against, 18:172, 20:49-55
 FK-037 against, 18:172
Streptolysin O, roxithromycin effect on, 20: 7-11

Streptomycin
 against enterococci, 20:61-67
 against *Enterococcus faecium*, 20:42
 against *Mycobacterium genavense*, 18:10

Strongyloides stercoralis
 pyrvium pamoate against, 18:19-23
 thiabendazole against, 18:19-23

Strongyloidiasis, postchemotherapy evaluation of, 18:19-23

Structural gene, encoding 10-kD antigen in *Mycobacterium tuberculosis*, 18:215- 218

Sucrose-phosphate-glutamate medium, virus survival in, 19:137-142

Sulfamethoxazole
 against *Mycobacterium avium*, 18:201-204
 against *Mycobacterium intracellulare*, 18: 201-204

Sulfisoxazole
 against *Mycobacterium avium*, 18:201-204
 against *Mycobacterium intracellulare*, 18: 201-204

Surgical intensive care unit, *Enterococcus faecalis* in, 19:197-202

Tazobactam
 against *Bacteroides capillosus*, 19:227-234
 against *Bacteroides fragilis*, 19:227-234
 against *Clostridium* spp., 19:227-234
 against *Eubacterium* spp., 19:227-234
 against *Fusobacterium* spp., 19:227-234
 against *Peptostreptococcus* spp., 19:227- 234

TechLab Tox-A enzyme immunoassay, for *Clostridium difficile*, 20:1-5

Teicoplanin, against *Enterococcus faecium*, 20:42
 Temmler CUT test, for *Helicobacter pylori*, 18:69, 70-74

Temofoxacin, against *Listeria monocytogenes*, 20:21-25

Tetracycline
 against *Enterococcus faecium*, 20:42
mecA gene and, 19:25-31
 against *Mycoplasma hominis*, 20:57-59
 against *Mycoplasma pneumoniae*, 20:57-59
 against *Neisseria gonorrhoeae*, 18:175-178
 against *Streptococcus milleri* group, 19:70- 73
 against *Ureaplasma urealyticum*, 20:57-59

Thermonuclease, heat-stable, for *Staphylococcus aureus*, 19:5-8

Thiabendazole, against *Strongyloides stercoralis*, 18:19-23

Thiamphenicol, against *Neisseria gonorrhoeae*, 19:121-127

Ticarcillin, against Gram-negative anaerobic rods, 18:25-30

Ticarcillin-clavulanate
 against *Bacteroides capillosus*, 19:227-234
 against *Bacteroides fragilis*, 19:227-234
 against *Clostridium* spp., 19:227-234
 against *Eubacterium* spp., 19:227-234
 against *Fusobacterium* spp., 19:227-234
 against Gram-negative bacilli, 18:25-30, 19:111-120
 against Gram-positive cocci, 19:111-120
 against *Peptostreptococcus* spp., 19:227-234
 against *Porphyromonas* spp., 19:227-234
 against *Prevotella* spp., 19:227-234
 in US national surveillance study, 19: 204-215
 against *Veillonella parvula*, 19:227-234

Ticarcillin-clavulanic acid
 against *Acinetobacter* spp., 19:151-156
 against *Citrobacter freundii*, 19:151-156
 against *Enterobacter cloacae*, 19:151-156
 against *Enterobacter* spp., 18:251-258
 against *Enterococcus faecalis*, 19:151-156
 against *Escherichia coli*, 19:151-156
 against *Klebsiella* spp., 18:251-258, 19: 151-156
 against *Proteus* spp., 19:151-156
 against *Pseudomonas aeruginosa*, 18:251- 258, 19:151-156
 against *Serratia marcescens*, 19:151-156
 against *Staphylococcus aureus*, 19:151-156

Time-kill assays
 of gentamicin against enterococci, 19:57- 60
 of *Pseudomonas aeruginosa* susceptibility, 19:39-46

Tissue impression smears, *Pneumocystis carinii* in, 18:197-199

TMP/SMZ. *See* Trimethoprim-sulfamethoxazole

Tobramycin
 against *Enterobacter* spp., 18:251-258
 against *Klebsiella* spp., 18:251-258
 against *Pseudomonas aeruginosa*, 18:251- 258, 19:39-46

Todd-Hewitt broth, *Streptococcus*, group B cultures and, 18:141-144

Torulopsis glabrata
 amphotericin B against, 19:10, 19:75-80
 D0870 against, 19:75-80
 fluconazole against, 19:10, 19:75-80, 19: 218-219
 5-fluorocytosine against, 19:10, 19:75-80, 19:218-219
 itraconazole against, 19:75-80

Toxic shock syndrome, *Staphylococcus aureus* and *Streptococcus pyogenes* in, 19: 245-247

Toxoplasma gondii, immunoassays for, 19: 19-24

Transbronchial biopsy, of *Coccidioides immitis*, 18:83-87

Transport media, virus survival in, 19:137- 142

Triazole
 against *Candida* spp., 19:75-80
 against *Torulopsis glabrata*, 19:75-80

Trimethoprim
 against *Mycobacterium avium*, 18:201-204
 against *Mycobacterium intracellulare*, 18: 201-204
 against *Streptococcus milleri* group, 19:70-73

Trimethoprim-sulfamethoxazole (TMP/ SMZ)
 against Gram-negative bacilli, 18:181-189
 against *Listeria monocytogenes*, 20:21-25
 against *Mycobacterium avium*, 18:201-204
 against *Mycobacterium chelonae*, 19:183- 186
 against *Mycobacterium fortuitum*, 19:183- 186
 against *Nocardia* spp., 19:101-110
 against *Pseudomonas stutzeri*, 19:51-56
Streptococcus group B cultures and, 18: 141-144

Tryptose phosphate broth, virus survival in, 19:137-142

Ulcerations, *Sporothrix schenckii* in, 18:111- 116

Ureaplasma urealyticum
 dirithromycin against, 20:57-59
 erythromycin against, 20:57-59
 macrolides against, 20:57-59
 tetracycline against, 20:57-59

Urease test systems, for *Helicobacter pylori*, 18:69-74

Urethral swabs, chlamydial antigen on, 18: 101-104

Urinary tract isolates
 cefdinir against, 18:31-39
 ciprofloxacin against, 18:49-56
 of coagulase-negative staphylococci, 18: 1-5
 of *Enterococcus faecalis*, 19:197-202
 of *Escherichia coli*, 18:263-265
 norfloxacin against, 18:49-56
 ofloxacin against, 18:49-56

Urine specimens
Chlamydia trachomatis in, 18:101-104, 20: 195-201
 enterococci in, 20:61-67
 leukocyte stability in refrigerated, 18:79- 81
Pseudomonas stutzeri in, 19:51-56

Vaccines, pneumococcal, 18:211-214

Vaginal swabs, *Streptococcus* group B on, 18:141-144

Vaginosis, bacterial, 20:213-220

Vancomycin

- against *Corynebacterium* spp., 19:171-173
- against enterococci, 20:61-67, 20:113-116
- against *Enterococcus faecium*, 18:105-109, 20:41-43
- against *Staphylococcus aureus*, 18:43
- against *Streptococcus milleri* group, 19:70-73
- in US national surveillance study, 19:204-215

Varicella-zoster virus (VZV)

- indirect immunofluorescence for, 20:117
- latex agglutination assay for, 20:117

Veillonella parvula

- cefotaxime against, 20:135-142
- cefoxitin against, 20:135-142
- ceftizoxime against, 20:135-142
- ceftriaxone-tazobactam against, 19:227-234, 20:135-142
- metronidazole against, 20:135-142
- piperacillin against, 20:135-142

Ventricular drain, *Candida* spp. in, 20:33-40

Vibrio cholerae

- in cholera, 20:119
- in Lebanese antimicrobial susceptibility study, 20:151-158

VIDAS enzyme immunoassay, for cytomegalovirus antibody, 20:109-112

Videk Immunodiagnostic Assay System, for chlamydial antigen, 18:101-104

Virocult medium, virus survival in, 19:137-142

Vi-specific latex agglutination, for *Salmonella typhi*, 18:75-78

Vitek AMS system, for vancomycin resistance in enterococci, 20:113-116

Vitek AutoMicrobic system

- for *Enterobacter* spp., 18:251-258
- for *Klebsiella* spp., 18:251-258
- for *Pseudomonas aeruginosa*, 18:251-258

Vitek GPI system, for staphylococci, 18:151-155

VZV. *See* Varicella-zoster virus

Water-hexadecan two-phase system, roxithromycin and, 20:7-11

Western-blot analysis, of lactoferrin interaction with *Salmonella* spp., 20:69-75

Wounds

- enterococci in, 20:61-67
- Enterococcus faecalis* in, 19:197-202
- Pseudomonas stutzeri* in, 19:51-56

Xanthomonas maltophilia

- amoxicillin-clavulanate against, 18:185
- cefaclor against, 18:185
- cefepime against, 18:167-173

cefixime against, 18:185

cefotaxime against, 18:61-68

ceftazidime against, 18:167-173

cefuroxime against, 18:185

ciprofloxacin against, 18:61-68, 18:185

DU-6859a against, 18:125

FK-037 against, 18:167-173, 20:27-32

fleroxacin against, 18:185

lomefloxacin against, 18:185

ofloxacin against, 18:185

Pasco Gram-negative nonfermenter system for, 19:61-63

Ro 23-9424 against, 18:61-68

Ro 25-0534 against, 18:61-68

trimethoprim-sulfamethoxazole against, 18:185

Xanthomonas spp.

- cefepime against, 19:33-38
- fluoroquinolones against, 18:181

Xho, in ribotyping *Pseudomonas cepacia*, 20:181-186

Yeast extract, *Streptococcus* group B cultures and, 18:141-144

Yeasts

- Etest for antifungal susceptibility of, 19:217-220
- microdilution testing for, 19:9-13

Yersinia enterocolitica, FK-307 against, 20:27-32

